Amgen (AMGN) 10-Q 30 Oct 19 2019 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2019	Oct. 23, 2019
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2019
Document Transition Report	false
Entity File Number	001-37702
Entity Registrant Name	Amgen Inc.
Entity Central Index Key	0000318154
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	95-3540776
Entity Address, Address Line One	One Amgen Center Drive
Entity Address, City or Town	Thousand Oaks
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91320-1799
City Area Code	805
Local Phone Number	447-1000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		594,183,541
The NASDAQ Global Select Market [Member] | Common Stock [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common stock, $0.0001 par value
Trading Symbol	AMGN
Security Exchange Name	NASDAQ
New York Stock Exchange [Member] | 1.250% Senior Notes Due 2022 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.250% Senior Notes Due 2022
Trading Symbol	AMGN22
Security Exchange Name	NYSE
New York Stock Exchange [Member] | 2.00% Senior Notes Due 2026 [Member]
Entity Information [Line Items]
Title of 12(b) Security	2.00% Senior Notes Due 2026
Trading Symbol	AMGN26
Security Exchange Name	NYSE

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Net income	$ 1,968	$ 1,859	$ 6,139	$ 6,466
Other comprehensive income (loss), net of reclassification adjustments and taxes:
Losses on foreign currency translation	(39)	(71)	(56)	(153)
Gains on cash flow hedges	86	41	27	270
Gains (losses) on available-for-sale securities	30	97	404	(237)
Other	0	(3)	6	(1)
Other comprehensive income (loss), net of taxes	77	64	381	(121)
Comprehensive income	$ 2,045	$ 1,923	$ 6,520	$ 6,345

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues:
Total revenues	$ 5,737	$ 5,904	$ 17,165	$ 17,517
Operating expenses:
Cost of sales	1,036	1,037	3,103	3,005
Research and development	1,001	926	2,804	2,555
Selling, general and administrative	1,223	1,293	3,637	3,773
Other	1	325	(5)	303
Total operating expenses	3,261	3,581	9,539	9,636
Operating income	2,476	2,323	7,626	7,881
Interest expense, net	313	355	988	1,040
Interest and other income, net	114	126	517	519
Income before income taxes	2,277	2,094	7,155	7,360
Provision for income taxes	309	235	1,016	894
Net income	$ 1,968	$ 1,859	$ 6,139	$ 6,466
Earnings per share:
Basic (in usd per share)	$ 3.29	$ 2.88	$ 10.08	$ 9.67
Diluted (in usd per share)	$ 3.27	$ 2.86	$ 10.01	$ 9.61
Shares used in calculation of earnings per share:
Basic (in shares)	599	645	609	669
Diluted (in shares)	602	649	613	673
Product sales [Member]
Revenues:
Product sales	$ 5,463	$ 5,510	$ 16,323	$ 16,532
Other revenues [Member]
Revenues:
Total revenues	$ 274	$ 394	$ 842	$ 985

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 11,415	$ 6,945
Marketable securities	9,438	22,359
Trade receivables, net	3,606	3,580
Inventories	3,243	2,940
Other current assets	3,349	1,794
Total current assets	31,051	37,618
Property, plant and equipment, net	4,901	4,958
Intangible assets, net	6,702	7,443
Goodwill	14,705	14,699
Other assets	2,176	1,698
Total assets	59,535	66,416
Current liabilities:
Accounts payable	1,005	1,207
Accrued liabilities	7,683	7,862
Current portion of long-term debt	2,049	4,419
Total current liabilities	10,737	13,488
Long-term debt	27,742	29,510
Long-term deferred tax liabilities	665	864
Long-term tax liabilities	7,921	8,770
Other noncurrent liabilities	1,543	1,284
Contingencies and commitments
Stockholders’ equity:
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding — 596.2 shares in 2019 and 629.6 shares in 2018	31,451	31,246
Accumulated deficit	(20,136)	(17,977)
Accumulated other comprehensive loss	(388)	(769)
Total stockholders’ equity	10,927	12,500
Total liabilities and stockholders’ equity	$ 59,535	$ 66,416

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Millions	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock and additional paid-in capital, par value (in usd per share)	$ 0.0001	$ 0.0001
Common stock and additional paid-in capital, shares authorized	2,750	2,750
Common stock and additional paid-in capital, shares outstanding	596.2	629.6

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Number of shares of common stock [Member]	Common stock and additional paid-in capital [Member]	Accumulated deficit [Member]	Accumulated other comprehensive loss [Member]
Beginning Balance, Shares at Dec. 31, 2017		722.2
Balance as of beginning of period at Dec. 31, 2017	$ 25,241		$ 30,992	$ (5,072)	$ (679)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for basic and diluted EPS	2,311			2,311
Other comprehensive income (loss), net of taxes	(306)				(306)
Dividends declared on common stock	(877)			(877)
Issuance of common stock in connection with the Company’s equity award programs, Shares		0.6
Issuance of common stock in connection with the Company’s equity award programs	5		5
Stock-based compensation expense	61		61
Tax impact related to employee stock-based compensation expense	(57)		(57)
Repurchases of common stock, Shares		(56.4)
Repurchases of common stock	(10,787)			(10,787)
Ending Balance, Shares at Mar. 31, 2018		666.4
Balance as of end of period at Mar. 31, 2018	15,620		31,001	(14,387)	(994)
Beginning Balance, Shares at Dec. 31, 2017		722.2
Balance as of beginning of period at Dec. 31, 2017	25,241		30,992	(5,072)	(679)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for basic and diluted EPS	6,466
Ending Balance, Shares at Sep. 30, 2018		640.5
Balance as of end of period at Sep. 30, 2018	14,349		31,145	(15,987)	(809)
Beginning Balance, Shares at Mar. 31, 2018		666.4
Balance as of beginning of period at Mar. 31, 2018	15,620		31,001	(14,387)	(994)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for basic and diluted EPS	2,296			2,296
Other comprehensive income (loss), net of taxes	121				121
Issuance of common stock in connection with the Company’s equity award programs, Shares		0.8
Issuance of common stock in connection with the Company’s equity award programs	19		19
Stock-based compensation expense	93		93
Tax impact related to employee stock-based compensation expense	(65)		(65)
Repurchases of common stock, Shares		(18.2)
Repurchases of common stock	(3,190)			(3,190)
Other	15			15
Ending Balance, Shares at Jun. 30, 2018		649
Balance as of end of period at Jun. 30, 2018	14,909		31,048	(15,266)	(873)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for basic and diluted EPS	1,859			1,859
Other comprehensive income (loss), net of taxes	64				64
Dividends declared on common stock				(867)
Issuance of common stock in connection with the Company’s equity award programs, Shares		0.2
Issuance of common stock in connection with the Company’s equity award programs	13		13
Stock-based compensation expense	94		94
Tax impact related to employee stock-based compensation expense	(10)		(10)
Repurchases of common stock, Shares		(8.7)
Repurchases of common stock	(1,713)			(1,713)
Ending Balance, Shares at Sep. 30, 2018		640.5
Balance as of end of period at Sep. 30, 2018	$ 14,349		31,145	(15,987)	(809)
Beginning Balance, Shares at Dec. 31, 2018	629.6	629.6
Balance as of beginning of period at Dec. 31, 2018	$ 12,500		31,246	(17,977)	(769)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for basic and diluted EPS	1,992			1,992
Other comprehensive income (loss), net of taxes	253				253
Dividends declared on common stock	(879)			(879)
Issuance of common stock in connection with the Company’s equity award programs, Shares		0.7
Issuance of common stock in connection with the Company’s equity award programs	6		6
Stock-based compensation expense	64		64
Tax impact related to employee stock-based compensation expense	(73)		(73)
Repurchases of common stock, Shares		(15.9)
Repurchases of common stock	(3,031)			(3,031)
Ending Balance, Shares at Mar. 31, 2019		614.4
Balance as of end of period at Mar. 31, 2019	$ 10,832		31,243	(19,895)	(516)
Beginning Balance, Shares at Dec. 31, 2018	629.6	629.6
Balance as of beginning of period at Dec. 31, 2018	$ 12,500		31,246	(17,977)	(769)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for basic and diluted EPS	$ 6,139
Ending Balance, Shares at Sep. 30, 2019	596.2	596.2
Balance as of end of period at Sep. 30, 2019	$ 10,927		31,451	(20,136)	(388)
Beginning Balance, Shares at Mar. 31, 2019		614.4
Balance as of beginning of period at Mar. 31, 2019	10,832		31,243	(19,895)	(516)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for basic and diluted EPS	2,179			2,179
Other comprehensive income (loss), net of taxes	51				51
Issuance of common stock in connection with the Company’s equity award programs, Shares		0.8
Issuance of common stock in connection with the Company’s equity award programs	23		23
Stock-based compensation expense	97		97
Tax impact related to employee stock-based compensation expense	(50)		(50)
Repurchases of common stock, Shares		(13.1)
Repurchases of common stock	(2,349)			(2,349)
Other	11			11
Ending Balance, Shares at Jun. 30, 2019		602.1
Balance as of end of period at Jun. 30, 2019	10,794		31,313	(20,054)	(465)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for basic and diluted EPS	1,968			1,968
Other comprehensive income (loss), net of taxes	77				77
Dividends declared on common stock	(880)			(880)
Issuance of common stock in connection with the Company’s equity award programs, Shares		0.3
Issuance of common stock in connection with the Company’s equity award programs	37		37
Stock-based compensation expense	108		108
Tax impact related to employee stock-based compensation expense	(7)		(7)
Repurchases of common stock, Shares		(6.2)
Repurchases of common stock	$ (1,170)			(1,170)
Ending Balance, Shares at Sep. 30, 2019	596.2	596.2
Balance as of end of period at Sep. 30, 2019	$ 10,927		$ 31,451	$ (20,136)	$ (388)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares	1 Months Ended				3 Months Ended
	Oct. 31, 2019	Aug. 31, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Mar. 31, 2018
Statement of Stockholders' Equity [Abstract]
Common stock, dividends declared per share (in usd per share)	$ 1.45	$ 1.45	$ 1.45	$ 1.45	$ 1.45	$ 1.45	$ 1.32	$ 1.32

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net income	$ 6,139	$ 6,466
Depreciation, amortization and other	1,504	1,456
Deferred income taxes	(172)	(294)
Other items, net	169	636
Changes in operating assets and liabilities, net of acquisitions:
Trade receivables, net	(63)	(234)
Inventories	(101)	(93)
Other assets	(269)	(110)
Accounts payable	(196)	(311)
Accrued income taxes, net	(128)	(384)
Long-term tax liabilities	(262)	204
Other liabilities	15	766
Net cash provided by operating activities	6,636	8,102
Cash flows from investing activities:
Purchases of marketable securities	(9,062)	(12,617)
Proceeds from sales of marketable securities	3,019	28,059
Proceeds from maturities of marketable securities	18,441	3,881
Cash paid, net of cash acquired	(177)	197
Purchases of property, plant and equipment	(430)	(513)
Other	(119)	(31)
Net cash provided by investing activities	11,672	18,976
Cash flows from financing activities:
Repayment of debt	(4,514)	(500)
Repurchases of common stock	(6,608)	(15,670)
Dividends paid	(2,649)	(2,667)
Other	(67)	(85)
Net cash used in financing activities	(13,838)	(18,922)
Increase in cash and cash equivalents	4,470	8,156
Cash and cash equivalents at beginning of period	6,945	3,800
Cash and cash equivalents at end of period	$ 11,415	$ 11,956

Summary of significant accounti

Summary of significant accounting policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Business Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics. Basis of presentation The financial information for the three and nine months ended September 30, 2019 and 2018 , is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year. The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2018 , and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2019 and June 30, 2019 . Principles of consolidation The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates. Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $8.2 billion and $7.8 billion as of September 30, 2019 and December 31, 2018 , respectively. Leases Adoption of new lease standard In February 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for the accounting and disclosure of leases. This new standard requires that lessees recognize the assets and liabilities that arise from leases on the balance sheet, including leases classified as operating leases, and that they disclose qualitative and quantitative information about leasing arrangements. The FASB subsequently issued additional amendments to address issues arising from the implementation of the new lease standard. We adopted this standard as of January 1, 2019, using the modified-retrospective method. This approach provides a method for recording existing leases at adoption. We used the adoption date as our date of initial application, and thus, comparative-period financial information is not presented for periods prior to the adoption date. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease classification. Adoption of the new standard resulted in total lease liabilities of $510 million and right-of-use (ROU) assets of $439 million as of January 1, 2019. The difference between the initial lease liabilities and the ROU assets is related primarily to previously existing lease liabilities. The standard did not materially impact our Condensed Consolidated Statements of Income and had no impact on our Condensed Consolidated Statements of Cash Flows. Our accounting policies under the new standard are described below. See Note 9, Leases. Lease recognition At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other assets, Accrued liabilities and Other noncurrent liabilities in our Condensed Consolidated Balance Sheets. ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate. Other recent accounting pronouncements In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary-impairment model. The new standard is effective for interim and annual periods beginning on January 1, 2020. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. We have substantially completed our impact assessment and do not currently anticipate a material impact on our condensed consolidated financial statements.

Business combinations

Business combinations	9 Months Ended
	Sep. 30, 2019
Business Combinations [Abstract]
Business combinations	Business combinations Nuevolution AB On July 15, 2019, we acquired all of the outstanding stock of Nuevolution AB (Nuevolution), a publicly traded, Denmark-based biotechnology company with a leading small-molecule-drug discovery platform, for total consideration of $183 million in cash. The transaction, which was accounted for as a business combination, expands our ability to discover novel small molecules against difficult-to-drug targets and with greater speed and efficiency. Nuevolution’s operations, which are not material, have been included in our condensed consolidated financial statements commencing on the acquisition date. We allocated the consideration to acquire Nuevolution to finite-lived intangible assets of $150 million , comprised primarily of technology rights for a drug discovery platform with an estimated useful life of 10 years ; goodwill of $26 million , which is not tax deductible; deferred tax liabilities of $22 million ; and other net assets of $29 million . The estimated fair values of intangible assets were determined primarily using a probability-weighted income approach, which discounts expected future cash flows to present value by using a discount rate that represents the estimated rate that market participants would use to value the intangible assets. Our accounting for this acquisition is preliminary and will be finalized upon completion of our analysis to determine the acquisition date fair values of certain assets acquired, tax-related items and the residual impact on goodwill. Otezla ® On August 25, 2019, we entered into an agreement with Celgene Corporation (Celgene) in connection with Celgene’s previously announced merger with Bristol-Myers Squibb Company (BMS) to acquire worldwide rights to Otezla ® (apremilast), the only oral, nonbiologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities for $13.4 billion

Revenues

Revenues	9 Months Ended
	Sep. 30, 2019
Revenue from Contract with Customer [Abstract]
Revenues	Revenues We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. Rest-of-world (ROW) revenues relate to products that are sold primarily in Europe. Revenues were as follows (in millions): Three months ended September 30, 2019 2018 US ROW Total US ROW Total Enbrel ® (etanercept) $ 1,323 $ 43 $ 1,366 $ 1,242 $ 50 $ 1,292 Neulasta ® (pegfilgrastim) 619 92 711 897 154 1,051 Prolia ® (denosumab) 425 205 630 354 178 532 XGEVA ® (denosumab) 356 120 476 323 110 433 Aranesp ® (darbepoetin alfa) 204 248 452 248 229 477 KYPROLIS ® (carfilzomib) 163 103 266 142 90 232 EPOGEN ® (epoetin alfa) 215 — 215 252 — 252 Sensipar ® /Mimpara ® (cinacalcet) 38 71 109 330 79 409 Other products 686 552 1,238 472 360 832 Total product sales (1) $ 4,029 $ 1,434 5,463 $ 4,260 $ 1,250 5,510 Other revenues 274 394 Total revenues $ 5,737 $ 5,904 Nine months ended September 30, 2019 2018 US ROW Total US ROW Total ENBREL $ 3,744 $ 136 $ 3,880 $ 3,544 $ 155 $ 3,699 Neulasta ® 2,231 325 2,556 2,854 452 3,306 Prolia ® 1,273 647 1,920 1,070 566 1,636 XGEVA ® 1,091 355 1,446 994 336 1,330 Aranesp ® 578 724 1,302 714 689 1,403 KYPROLIS ® 483 295 778 430 287 717 EPOGEN ® 657 — 657 746 — 746 Sensipar ® /Mimpara ® 216 228 444 1,069 257 1,326 Other products 1,889 1,451 3,340 1,353 1,016 2,369 Total product sales (1) $ 12,162 $ 4,161 16,323 $ 12,774 $ 3,758 16,532 Other revenues 842 985 Total revenues $ 17,165 $ 17,517 ____________ (1) Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2019 and 2018

Income taxes

Income taxes	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income taxes	Income taxes Effective tax rates for the three and nine months ended September 30, 2019 , were 13.6% and 14.2% , respectively, compared with 11.2% and 12.1% , respectively, for the corresponding periods of the prior year. The increases in our effective tax rates for the three and nine months ended September 30, 2019 , were due primarily to a prior-year tax benefit associated with intercompany sales under U.S. corporate tax reform. The effective tax rates differ from the federal statutory rate primarily as a result of foreign earnings from the Company’s operations conducted in Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes and that is subject to tax incentive grants through 2035; these earnings are subject to U.S. tax at a reduced rate of 10.5%. The U.S. territory of Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. The rate of 4% is effective through December 31, 2027. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred. One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes may arise with authorities involving issues of the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. As previously disclosed, we received a Revenue Agent Report (RAR) from the Internal Revenue Service (IRS) for the years 2010, 2011 and 2012. The RAR proposes to make significant adjustments that relate primarily to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. In November 2017, we received a modified RAR that revised the IRS’s calculation but continued to propose substantial adjustments. We disagree with the proposed adjustments and are pursuing resolution with the IRS administrative appeals office, which currently has jurisdiction over the matter. If we deem necessary, we will vigorously contest the proposed adjustments through the judicial process. Final resolution of this complex matter is not likely within the next 12 months and could have a material impact on our condensed consolidated financial statements. We believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes, the ultimate resolution of any tax matters may result in payments greater or less than amounts accrued. We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009. In addition, we are currently under examination by a number of other state and foreign tax jurisdictions. During the three and nine months ended September 30, 2019 , the gross amounts of our unrecognized tax benefits (UTBs) increased $50 million and $160 million , respectively, as a result of tax positions taken during the current year. Substantially all of the UTBs as of September 30, 2019 , if recognized, would affect our effective tax rate.

Earnings per share

Earnings per share	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Earnings per share	Earnings per share The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which include primarily shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method. The computations for basic and diluted EPS were as follows (in millions, except per-share data): Three months ended Nine months ended 2019 2018 2019 2018 Income (Numerator): Net income for basic and diluted EPS $ 1,968 $ 1,859 $ 6,139 $ 6,466 Shares (Denominator): Weighted-average shares for basic EPS 599 645 609 669 Effect of dilutive securities 3 4 4 4 Weighted-average shares for diluted EPS 602 649 613 673 Basic EPS $ 3.29 $ 2.88 $ 10.08 $ 9.67 Diluted EPS $ 3.27 $ 2.86 $ 10.01 $ 9.61 For the three and nine months ended September 30, 2019 and 2018 , the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.

Investments

Investments	9 Months Ended
	Sep. 30, 2019
Investments, Debt and Equity Securities [Abstract]
Investments	Investments Available-for-sale investments The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions): Types of securities as of September 30, 2019 Amortized cost Gross unrealized gains Gross unrealized losses Fair values U.S. Treasury notes $ 1,164 $ 3 $ — $ 1,167 U.S. Treasury bills 2,494 — — 2,494 Other government-related debt securities: U.S. — — — — Foreign and other 896 29 — 925 Corporate debt securities: Financial 2,116 24 — 2,140 Industrial 2,002 23 — 2,025 Other 531 6 — 537 Residential-mortgage-backed securities 512 4 — 516 Other mortgage- and asset-backed securities 43 — — 43 Money market mutual funds 8,017 — — 8,017 Other short-term interest-bearing securities 2,363 — — 2,363 Total interest-bearing securities $ 20,138 $ 89 $ — $ 20,227 Types of securities as of December 31, 2018 Amortized cost Gross unrealized gains Gross unrealized losses Fair values U.S. Treasury notes $ 2,710 $ — $ (47 ) $ 2,663 U.S. Treasury bills 8,191 — — 8,191 Other government-related debt securities: U.S. 112 — (2 ) 110 Foreign and other 972 1 (41 ) 932 Corporate debt securities: Financial 2,778 — (81 ) 2,697 Industrial 2,603 — (99 ) 2,504 Other 583 — (21 ) 562 Residential-mortgage-backed securities 1,458 — (36 ) 1,422 Other mortgage- and asset-backed securities 483 — (14 ) 469 Money market mutual funds 5,659 — — 5,659 Other short-term interest-bearing securities 3,515 — — 3,515 Total interest-bearing securities $ 29,064 $ 1 $ (341 ) $ 28,724 The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions): Condensed Consolidated Balance Sheets locations September 30, December 31, Cash and cash equivalents $ 10,789 $ 6,365 Marketable securities 9,438 22,359 Total interest-bearing securities $ 20,227 $ 28,724 Cash and cash equivalents in the above table excludes bank account cash of $626 million and $580 million as of September 30, 2019 and December 31, 2018 , respectively. The fair values of interest-bearing securities by contractual maturity, except for mortgage- and asset-backed securities that do not have a single maturity date, were as follows (in millions): Contractual maturities September 30, December 31, Maturing in one year or less $ 12,941 $ 17,424 Maturing after one year through three years 4,855 3,356 Maturing after three years through five years 1,226 5,168 Maturing after five years through ten years 646 885 Mortgage- and asset-backed securities 559 1,891 Total interest-bearing securities $ 20,227 $ 28,724 For the three months ended September 30, 2019 and 2018 , realized gains on interest-bearing securities were $21 million and $5 million , respectively, and realized losses on interest-bearing securities were $24 million and $108 million , respectively. For the nine months ended September 30, 2019 and 2018 , realized gains on interest-bearing securities were $23 million and $27 million , respectively, and realized losses on interest-bearing securities were $32 million and $379 million , respectively. Realized gains and losses on interest-bearing securities are recorded in Interest and other income, net, in the Condensed Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method. As of September 30, 2019, we had $1.1 billion in receivables related to sales of securities, which were recorded in Other current assets in the Condensed Consolidated Balance Sheets. There were no receivables related to sales of securities as of December 31, 2018. As of September 30, 2019, aggregate gross unrealized losses of interest-bearing securities were not material. As of December 31, 2018, the fair values and gross unrealized losses of interest-bearing securities in an unrealized loss position aggregated by type and length of time that the securities have been in a continuous loss position were as follows (in millions): Less than 12 months 12 months or more Types of securities as of December 31, 2018 Fair values Unrealized losses Fair values Unrealized losses U.S. Treasury notes $ 1,219 $ (21 ) $ 1,444 $ (26 ) Other government-related debt securities: U.S. — — 110 (2 ) Foreign and other 631 (31 ) 240 (10 ) Corporate debt securities: Financial 1,968 (59 ) 718 (22 ) Industrial 1,898 (81 ) 529 (18 ) Other 529 (20 ) 28 (1 ) Residential-mortgage-backed securities 576 (14 ) 840 (22 ) Other mortgage- and asset-backed securities 17 — 451 (14 ) Total $ 6,838 $ (226 ) $ 4,360 $ (115 ) The primary objective of our investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer. We review our available-for-sale investments for other-than-temporary declines in fair value below our cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. The evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below our cost basis as well as adverse conditions related specifically to the security, such as any changes to the credit rating of the security and the intent to sell or whether we will more likely than not be required to sell the security before recovery of its amortized cost basis. Our assessment of whether a security is other-than-temporarily impaired could change in the future based on new developments or changes in assumptions related to that particular security. As of September 30, 2019 and December 31, 2018 , we believe the cost bases for our available-for-sale investments were recoverable in all material respects. Equity securities We held investments in equity securities with readily determinable fair values of $277 million and $176 million as of September 30, 2019 and December 31, 2018 , respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. Gains and losses recognized on equity securities with readily determinable fair values, including gains and losses recognized on sales, were not material for the three and nine months ended September 30, 2019 and 2018 . As of September 30, 2019 and December 31, 2018 , respectively, we held investments of $170 million and $222 million in equity securities without readily determinable fair values, which are included in Other assets in the Condensed Consolidated Balance Sheets. Adjustments to the carrying values of these securities were not material for the three and nine months ended September 30, 2019 and 2018 . Limited partnership investments We held limited partnership investments of $319 million and $285 million as of September 30, 2019 and December 31, 2018 , respectively, which are included in Other assets in the Condensed Consolidated Balance Sheets. These investments are measured by using the net asset values of the underlying investments as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of September 30, 2019 , unfunded additional commitments to be made during the next several years for these investments were not material. Gains and losses recognized on our limited partnership investments were not material for the three and nine months ended September 30, 2019 and 2018 .

Inventories

Inventories	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consisted of the following (in millions): September 30, December 31, Raw materials $ 324 $ 257 Work in process 1,923 1,660 Finished goods 996 1,023 Total inventories $ 3,243 $ 2,940

Goodwill and other intangible a

Goodwill and other intangible assets	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets	Goodwill and other intangible assets Goodwill The change in the carrying amount of goodwill was as follows (in millions): Nine months ended Beginning balance $ 14,699 Addition from Nuevolution acquisition 26 Currency translation adjustment (20 ) Ending balance $ 14,705 Other intangible assets Other intangible assets consisted of the following (in millions): September 30, 2019 December 31, 2018 Gross carrying amounts Accumulated amortization Other intangible assets, net Gross carrying amounts Accumulated amortization Other intangible assets, net Finite-lived intangible assets: Developed-product-technology rights $ 12,548 $ (7,978 ) $ 4,570 $ 12,573 $ (7,479 ) $ 5,094 Licensing rights 3,761 (2,286 ) 1,475 3,772 (2,032 ) 1,740 Marketing-related rights 1,209 (972 ) 237 1,297 (1,019 ) 278 Research and development technology rights 1,266 (922 ) 344 1,148 (872 ) 276 Total finite-lived intangible assets 18,784 (12,158 ) 6,626 18,790 (11,402 ) 7,388 Indefinite-lived intangible assets: In-process research and development 76 — 76 55 — 55 Total other intangible assets $ 18,860 $ (12,158 ) $ 6,702 $ 18,845 $ (11,402 ) $ 7,443 Developed-product-technology rights consists of rights related to marketed products acquired in business combinations. Licensing rights consists primarily of contractual rights acquired in business combinations to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and up-front payments associated with royalty obligations for marketed products. Marketing-related rights consists primarily of rights related to the sale and distribution of marketed products. Research and development (R&D) technology rights pertains to technology used in R&D that have alternative future uses. R&D technology rights include assets acquired with the Nuevolution acquisition in 2019. See Note 2, Business combinations. In-process research and development (IPR&D) consists of R&D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. We review IPR&D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval. During the three months ended September 30, 2019 and 2018 , we recognized amortization associated with our finite-lived intangible assets of $318 million and $331 million , respectively. During the nine months ended September 30, 2019 and 2018 , we recognized amortization associated with our finite-lived intangible assets of $948 million and $983 million , respectively. Amortization of intangible assets is included primarily in Cost of sales in the Condensed Consolidated Statements of Income. The total estimated amortization for our finite-lived intangible assets for the remaining three months ending December 31, 2019 , and the years ending December 31, 2020 , 2021 , 2022 , 2023 and 2024 , are $0.3 billion , $1.2 billion , $1.0 billion , $0.9 billion , $0.9 billion and $0.9 billion , respectively.

Leases

Leases	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Leases	Leases On January 1, 2019, we adopted a new accounting standard that amends the guidance for the accounting and reporting of leases. Certain required disclosures have been made on a prospective basis in accordance with the guidance of the standard. See Note 1, Summary of significant accounting policies. We lease certain facilities and equipment related primarily to administrative, R&D and sales and marketing activities. Leases with terms of 12 months or less are expensed on a straight-line basis over the term and are not recorded in the Condensed Consolidated Balance Sheets. Most leases include one or more options to renew, with renewal terms that may extend the lease term up to seven years . The exercise of lease renewal options is at our sole discretion. In addition, some of our lease agreements include rental payments adjusted periodically for inflation. Our lease agreements neither contain residual value guarantees nor impose significant restrictions or covenants. We sublease certain real estate to third parties. Our sublease portfolio consists of operating leases from former R&D and administrative space. The following table summarizes information related to our leases, all of which are classified as operating, included in our Condensed Consolidated Balance Sheets (in millions): Condensed Consolidated Balance Sheets locations September 30, 2019 Assets: Other assets $ 422 Liabilities: Accrued liabilities $ 135 Other noncurrent liabilities 351 Total lease liabilities $ 486 The components of net lease costs were as follows (in millions): Lease costs Three months ended September 30, 2019 Nine months ended Operating (1) $ 50 $ 149 Sublease income (8 ) (25 ) Total net lease costs $ 42 $ 124 ____________ (1) Includes short-term leases and variable lease costs, which were not material for the three and nine months ended September 30, 2019 . Maturities of lease liabilities as of September 30, 2019 , were as follows (in millions): Maturity dates Operating leases Remaining three months ending December 31, 2019 $ 31 2020 157 2021 137 2022 77 2023 65 Thereafter 55 Total lease payments (1) 522 Less imputed interest (36 ) Present value of lease liabilities $ 486 ____________ (1) Includes future rental commitments for abandoned leases of $189 million . We expect to receive total future rental income of $149 million related to noncancelable subleases for abandoned facilities. The weighted-average remaining lease term and weighted-average discount rate of our leases were four years and 3.31% , respectively, as of September 30, 2019 . Cash and noncash information related to our leases was as follows (in millions): Three months ended September 30, 2019 Nine months ended Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 42 $ 115 ROU assets obtained in exchange for lease obligations: Operating leases $ 29 $ 83

Financing arrangements

Financing arrangements	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Financing arrangements	Financing arrangements Our borrowings consisted of the following (in millions): September 30, December 31, 5.70% notes due 2019 (5.70% 2019 Notes) $ — $ 1,000 1.90% notes due 2019 (1.90% 2019 Notes) — 700 Floating Rate Notes due 2019 — 550 2.20% notes due 2019 (2.20% 2019 Notes) — 1,400 2.125% €675 million notes due 2019 (2.125% 2019 euro Notes) — 774 4.50% notes due 2020 (4.50% 2020 Notes) 300 300 2.125% notes due 2020 (2.125% 2020 Notes) 750 750 Floating Rate Notes due 2020 300 300 2.20% notes due 2020 (2.20% 2020 Notes) 700 700 3.45% notes due 2020 (3.45% 2020 Notes) 900 900 4.10% notes due 2021 (4.10% 2021 Notes) 1,000 1,000 1.85% notes due 2021 (1.85% 2021 Notes) 750 750 3.875% notes due 2021 (3.875% 2021 Notes) 1,750 1,750 1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) 1,362 1,433 2.70% notes due 2022 (2.70% 2022 Notes) 500 500 2.65% notes due 2022 (2.65% 2022 Notes) 1,500 1,500 3.625% notes due 2022 (3.625% 2022 Notes) 750 750 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) 702 713 2.25% notes due 2023 (2.25% 2023 Notes) 750 750 3.625% notes due 2024 (3.625% 2024 Notes) 1,400 1,400 3.125% notes due 2025 (3.125% 2025 Notes) 1,000 1,000 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) 817 860 2.60% notes due 2026 (2.60% 2026 Notes) 1,250 1,250 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) 584 606 3.20% notes due 2027 (3.20% 2027 Notes) 1,000 1,000 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) 860 893 6.375% notes due 2037 (6.375% 2037 Notes) 552 552 6.90% notes due 2038 (6.90% 2038 Notes) 291 291 6.40% notes due 2039 (6.40% 2039 Notes) 466 466 5.75% notes due 2040 (5.75% 2040 Notes) 412 412 4.95% notes due 2041 (4.95% 2041 Notes) 600 600 5.15% notes due 2041 (5.15% 2041 Notes) 974 974 5.65% notes due 2042 (5.65% 2042 Notes) 487 487 5.375% notes due 2043 (5.375% 2043 Notes) 261 261 4.40% notes due 2045 (4.40% 2045 Notes) 2,250 2,250 4.563% notes due 2048 (4.563% 2048 Notes) 1,415 1,415 4.663% notes due 2051 (4.663% 2051 Notes) 3,541 3,541 Other notes due 2097 100 100 Unamortized bond discounts, premiums and issuance costs, net (874 ) (896 ) Fair value adjustments 391 (53 ) Total carrying value of debt 29,791 33,929 Less current portion (2,049 ) (4,419 ) Total long-term debt $ 27,742 $ 29,510 There are no material differences between the effective interest rates and coupon rates of any of our borrowings, except for the 4.563% 2048 Notes and the 4.663% 2051 Notes, which have effective interest rates of 6.3% and 5.6% , respectively.

Stockholders' equity

Stockholders' equity	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Stockholders' equity	Stockholders’ equity Stock repurchase program Activity under our stock repurchase program, on a trade date basis, was as follows (in millions): 2019 2018 Shares Dollars Shares * Dollars First quarter 15.9 $ 3,031 56.4 $ 10,787 Second quarter 13.1 2,349 18.2 3,190 Third quarter 6.2 1,170 8.7 1,713 Total stock repurchases 35.2 $ 6,550 83.4 $ 15,690 * Total shares do not add due to rounding. In May 2019, our Board of Directors increased the amount authorized under our stock repurchase program by an additional $5.0 billion . As of September 30, 2019 , $3.6 billion of authorization remained available under our stock repurchase program. Dividends In August 2019, March 2019 and December 2018, the Board of Directors declared quarterly cash dividends of $1.45 per share, which were paid in September 2019, June 2019 and March 2019, respectively. In October 2019, the Board of Directors declared a quarterly cash dividend of $1.45 per share, which will be paid on December 6, 2019. Accumulated other comprehensive income (loss) The components of Accumulated other comprehensive income (loss) (AOCI) were as follows (in millions): Foreign currency translation Cash flow hedges Available-for-sale securities Other AOCI Balance as of December 31, 2018 $ (670 ) $ 241 $ (338 ) $ (2 ) $ (769 ) Foreign currency translation adjustments (13 ) — — — (13 ) Unrealized gains — 30 218 — 248 Reclassification adjustments to income — 28 4 — 32 Income taxes — (13 ) (1 ) — (14 ) Balance as of March 31, 2019 (683 ) 286 (117 ) (2 ) (516 ) Foreign currency translation adjustments (4 ) — — — (4 ) Unrealized (losses) gains — (96 ) 161 — 65 Reclassification adjustments to income — (36 ) 2 — (34 ) Other — — — 6 6 Income taxes — 28 (10 ) — 18 Balance as of June 30, 2019 (687 ) 182 36 4 (465 ) Foreign currency translation adjustments (39 ) — — — (39 ) Unrealized gains — 71 35 — 106 Reclassification adjustments to income — 38 3 — 41 Income taxes — (23 ) (8 ) — (31 ) Balance as of September 30, 2019 $ (726 ) $ 268 $ 66 $ 4 $ (388 ) Reclassifications out of AOCI and into earnings were as follows (in millions): Three months ended September 30, Components of AOCI 2019 2018 Condensed Consolidated Statements of Income locations Cash flow hedges: Foreign currency contract gains $ 26 $ 3 Product sales Cross-currency swap contract losses (64 ) (36 ) Interest and other income, net (38 ) (33 ) Income before income taxes 8 7 Provision for income taxes $ (30 ) $ (26 ) Net income Available-for-sale securities: Net realized losses $ (3 ) $ (103 ) Interest and other income, net — 1 Provision for income taxes $ (3 ) $ (102 ) Net income Nine months ended September 30, Components of AOCI 2019 2018 Condensed Consolidated Statements of Income locations Cash flow hedges: Foreign currency contract gains (losses) $ 62 $ (51 ) Product sales Cross-currency swap contract losses (92 ) (170 ) Interest and other income, net (30 ) (221 ) Income before income taxes 6 47 Provision for income taxes $ (24 ) $ (174 ) Net income Available-for-sale securities: Net realized losses $ (9 ) $ (352 ) Interest and other income, net — 3 Provision for income taxes $ (9 ) $ (349 ) Net income

Fair value measurement

Fair value measurement	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Fair value measurement	Fair value measurement To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows: Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access Level 2 — Valuations for which all significant inputs are observable either directly or indirectly—other than Level 1 inputs Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement. The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions): Quoted prices in Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Fair value measurement as of September 30, 2019, using: Total Assets: Interest-bearing securities: U.S. Treasury notes $ 1,167 $ — $ — $ 1,167 U.S. Treasury bills 2,494 — — 2,494 Other government-related debt securities: U.S. — — — — Foreign and other — 925 — 925 Corporate debt securities: Financial — 2,140 — 2,140 Industrial — 2,025 — 2,025 Other — 537 — 537 Residential-mortgage-backed securities — 516 — 516 Other mortgage- and asset-backed securities — 43 — 43 Money market mutual funds 8,017 — — 8,017 Other short-term interest-bearing securities — 2,363 — 2,363 Equity securities 277 — — 277 Derivatives: Foreign currency contracts — 339 — 339 Cross-currency swap contracts — 12 — 12 Interest rate swap contracts — 354 — 354 Total assets $ 11,955 $ 9,254 $ — $ 21,209 Liabilities: Derivatives: Foreign currency contracts $ — $ 6 $ — $ 6 Cross-currency swap contracts — 478 — 478 Contingent consideration obligations — — 62 62 Total liabilities $ — $ 484 $ 62 $ 546 Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Fair value measurement as of December 31, 2018, using: Total Assets: Interest-bearing securities: U.S. Treasury notes $ 2,663 $ — $ — $ 2,663 U.S. Treasury bills 8,191 — — 8,191 Other government-related debt securities: U.S. — 110 — 110 Foreign and other — 932 — 932 Corporate debt securities: Financial — 2,697 — 2,697 Industrial — 2,504 — 2,504 Other — 562 — 562 Residential-mortgage-backed securities — 1,422 — 1,422 Other mortgage- and asset-backed securities — 469 — 469 Money market mutual funds 5,659 — — 5,659 Other short-term interest-bearing securities — 3,515 — 3,515 Equity securities 176 — — 176 Derivatives: Foreign currency contracts — 182 — 182 Cross-currency swap contracts — 170 — 170 Interest rate swap contracts — 56 — 56 Total assets $ 16,689 $ 12,619 $ — $ 29,308 Liabilities: Derivatives: Foreign currency contracts $ — $ 26 $ — $ 26 Cross-currency swap contracts — 401 — 401 Interest rate swap contracts — 149 — 149 Contingent consideration obligations — — 72 72 Total liabilities $ — $ 576 $ 72 $ 648 Interest-bearing and equity securities The fair values of our U.S. Treasury securities, money market mutual funds and equity securities are based on quoted market prices in active markets, with no valuation adjustment. Most of our other government-related and corporate debt securities are investment grade and have maturity dates of five years or less from the balance sheet date. Our other government-related debt securities portfolio is composed of securities with weighted-average credit ratings of BBB+ or equivalent by Standard & Poor’s Financial Services LLC (S&P), Moody’s Investors Service, Inc. (Moody’s), or Fitch Ratings, Inc. (Fitch); and our corporate debt securities portfolio has weighted-average credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry-standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs. Our residential-mortgage-, other-mortgage- and asset-backed-securities portfolio is composed entirely of senior tranches with credit ratings of AAA by S&P, Moody’s or Fitch. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry-standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly to estimate fair value. The inputs include reported trades of and broker-dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment or default projections based on historical data; and other observable inputs. We value our other short-term interest-bearing securities at amortized cost, which approximates fair value given their near-term maturity dates. Derivatives All of our foreign currency forward and option derivative contracts have maturities of three years or less, and all are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, the London Interbank Offered Rate (LIBOR), swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts include implied volatility measures. These inputs, when applicable, are at commonly quoted intervals. See Note 13, Derivative instruments. Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency-basis swap spreads. See Note 13, Derivative instruments. Our interest rate swap contracts are with counterparties that have minimum credit ratings of A– or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by using an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include LIBOR, swap rates and obligor credit default swap rates. See Note 13, Derivative instruments. Contingent consideration obligations As a result of our business combinations, we have incurred contingent consideration obligations. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&D and commercial sales organizations. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Condensed Consolidated Statements of Income. Changes in the carrying amounts of contingent consideration obligations for the three and nine months ended September 30, 2019 and 2018 , were not material. During the three and nine months ended September 30, 2019 and 2018 , there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis, except with respect to the 2018 discontinuance of the internal development of a nonkey program resulting in an impairment of an IPR&D asset of $330 million , which was recognized in Other operating expenses in the Condensed Consolidated Statements of Income and included in Other items, net, in the Condensed Consolidated Statements of Cash Flows. Summary of the fair values of other financial instruments Cash equivalents The fair values of cash equivalents approximate their carrying values due to the short-term nature of such financial instruments. Borrowings We estimated the fair values of our borrowings by using Level 2 inputs. As of September 30, 2019 and December 31, 2018 , the aggregate fair values of our borrowings were $33.3 billion and $35.0 billion , respectively, and the carrying values were $29.8 billion and $33.9 billion , respectively.

Derivative instruments

Derivative instruments	9 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative instruments	Derivative instruments The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes. Cash flow hedges We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates associated primarily with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are offset partially by corresponding increases and decreases in the cash flows from our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations with regard to our international product sales, we enter into foreign currency forward and option contracts to hedge a portion of our projected international product sales primarily over a three-year time horizon , with, at any given point in time, a higher percentage of nearer-term projected product sales being hedged than in successive periods. As of September 30, 2019 and December 31, 2018 , we had outstanding foreign currency forward contracts with aggregate notional amounts of $4.6 billion and $4.5 billion , respectively. As of December 31, 2018, we had outstanding foreign currency option contracts with an aggregate notional amount of $21 million and no such outstanding contracts as of September 30, 2019. We have designated these foreign currency forward and foreign currency option contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Condensed Consolidated Balance Sheets, and we reclassify them to Product sales in the Condensed Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings. To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros, pounds sterling and Swiss francs and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the lives of the contracts by paying U.S. dollars and receiving euros, pounds sterling and Swiss francs. In addition, we will pay U.S. dollars to and receive euros, pounds sterling and Swiss francs from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros, pounds sterling and Swiss francs to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to Interest and other income, net, in the Condensed Consolidated Statements of Income in the same periods during which the hedged debt affects earnings. The notional amounts and interest rates of our cross-currency swaps as of September 30, 2019 , were as follows (notional amounts in millions): Foreign currency U.S. dollars Hedged notes Notional amounts Interest rates Notional amounts Interest rates 1.25% 2022 euro Notes € 1,250 1.3 % $ 1,388 3.2 % 0.41% 2023 Swiss franc Bonds CHF 700 0.4 % $ 704 3.4 % 2.00% 2026 euro Notes € 750 2.0 % $ 833 3.9 % 5.50% 2026 pound sterling Notes £ 475 5.5 % $ 747 6.0 % 4.00% 2029 pound sterling Notes £ 700 4.0 % $ 1,111 4.5 % During the three months ended September 30, 2019, our 2.125% 2019 euro Notes matured, and the related cross-currency swaps were settled. In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI i n the Condensed Consolidated Balance Sheets and are amortized into Interest expense, net, in the Condensed Consolidated Statements of Income over the lives of the associated debt issuances. Amounts recognized in connection with forward interest rate swaps during the nine months ended September 30, 2019 , and amounts expected to be recognized during the subsequent 12 months are not material. The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions): Three months ended Nine months ended Derivatives in cash flow hedging relationships 2019 2018 2019 2018 Foreign currency contracts $ 176 $ 41 $ 245 $ 233 Cross-currency swap contracts (105 ) (22 ) (240 ) (99 ) Total unrealized gains $ 71 $ 19 $ 5 $ 134 Fair value hedges To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate LIBOR-based coupons over the terms of the related hedge contracts. As of September 30, 2019 and December 31, 2018 , we had interest rate swap contracts with aggregate notional amounts of $9.55 billion and $10.95 billion , respectively, that hedge certain portions of our long-term debt issuances. For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Condensed Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining life of the previously hedged debt. The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions): Carrying amounts of hedged liabilities (1) Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities (2) Condensed Consolidated Balance Sheets locations September 30, 2019 December 31, 2018 September 30, 2019 December 31, 2018 Current portion of long-term debt $ — $ 2,396 $ — $ (3 ) Long-term debt $ 9,811 $ 9,361 $ 391 $ (50 ) ____________ (1) Current portion of long-term debt includes $1.0 billion of carrying value with discontinued hedging relationships as of December 31, 2018 . Long-term debt includes $136 million and $137 million of carrying value with discontinued hedging relationships as of September 30, 2019 and December 31, 2018 , respectively. (2) Current portion of long-term debt includes $3 million of hedging adjustments on discontinued hedging relationships as of December 31, 2018. Long-term debt includes $36 million and $37 million of hedging adjustments on discontinued hedging relationships as of September 30, 2019 and December 31, 2018 , respectively. Impact of hedging transactions The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions): Three months ended September 30, 2019 Nine months ended September 30, 2019 Product sales Interest and other income, net Interest (expense), net Product sales Interest and other income, net Interest (expense), net Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income $ 5,463 $ 114 $ (313 ) $ 16,323 $ 517 $ (988 ) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ 26 $ — $ — $ 62 $ — $ — Cross-currency swap contracts $ — $ (64 ) $ — $ — $ (92 ) $ — (Losses) gains on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ (96 ) $ — $ — $ (444 ) Derivatives designated as hedging instruments $ — $ — $ 96 $ — $ — $ 447 Three months ended September 30, 2018 Nine months ended September 30, 2018 Product sales Interest and other income, net Interest (expense), net Product sales Interest and other income, net Interest (expense), net Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income $ 5,510 $ 126 $ (355 ) $ 16,532 $ 519 $ (1,040 ) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ 3 $ — $ — $ (51 ) $ — $ — Cross-currency swap contracts $ — $ (36 ) $ — $ — $ (170 ) $ — Gains (losses) on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ 48 $ — $ — $ 278 Derivatives designated as hedging instruments $ — $ — $ (44 ) $ — $ — $ (259 ) __________ (1) Gains (losses) on hedged items do not completely offset (losses) gains on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships. No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of September 30, 2019 , we expected to reclassify $97 million of net gains on our foreign currency and cross-currency swap contracts out of AOCI and into earnings during the next 12 months. Derivatives not designated as hedges To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of September 30, 2019 and December 31, 2018 , the total notional amounts of these foreign currency forward contracts were $857 million and $737 million , respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the three and nine months ended September 30, 2019 and 2018 . The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions): Derivative assets Derivative liabilities September 30, 2019 Condensed Consolidated Balance Sheets locations Fair values Condensed Consolidated Balance Sheets locations Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other assets $ 339 Accrued liabilities/ Other noncurrent liabilities $ 6 Cross-currency swap contracts Other current assets/ Other assets 12 Accrued liabilities/ Other noncurrent liabilities 478 Interest rate swap contracts Other current assets/ Other assets 354 Accrued liabilities/ Other noncurrent liabilities — Total derivatives designated as hedging instruments 705 484 Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets — Accrued liabilities — Total derivatives not designated as hedging instruments — — Total derivatives $ 705 $ 484 Derivative assets Derivative liabilities December 31, 2018 Condensed Consolidated Balance Sheets locations Fair values Condensed Consolidated Balance Sheets locations Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other assets $ 181 Accrued liabilities/ Other noncurrent liabilities $ 26 Cross-currency swap contracts Other current assets/ Other assets 170 Accrued liabilities/ Other noncurrent liabilities 401 Interest rate swap contracts Other current assets/ Other assets 56 Accrued liabilities/ Other noncurrent liabilities 149 Total derivatives designated as hedging instruments 407 576 Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets 1 Accrued liabilities — Total derivatives not designated as hedging instruments 1 — Total derivatives $ 408 $ 576 Our derivative contracts that were in liability positions as of September 30, 2019 , contain certain credit-risk-related contingent provisions that would be triggered if (i) we were to undergo a change in control and (ii) our or the surviving entity’s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right but not the obligation to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur. The cash flow effects of our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash used in financing activities.

Contingencies and commitments

Contingencies and commitments	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Contingencies and commitments	Contingencies and commitments Contingencies In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See our Annual Report on Form 10-K for the year ended December 31, 2018 , Part I, Item 1A. Risk Factors— Our business may be affected by litigation and government investigations. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote; in Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2018; or in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2019 and June 30, 2019. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing; in Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2018; or in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2019 and June 30, 2019, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which, in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing; in Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2018; or in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2019 and June 30, 2019, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows. Certain recent developments concerning our legal proceedings and other matters are discussed below: Novartis Breach of Contract Action On September 17, 2019 and October 8, 2019, Novartis Pharma AG and Amgen, respectively, each filed its motion for judgment on the pleadings. Sensipar ® (cinacalcet) Litigation Cipla Ltd. v. Amgen Inc. On October 15, 2019, Amgen moved to dismiss Cipla Limited and Cipla USA, Inc.’s (collectively, Cipla) antitrust and fraud claims brought in the U.S. District Court for the District of Delaware (the Delaware District Court) for lack of standing and failure to state a claim. Abbreviated New Drug Application (ANDA) Patent Litigation Amgen Inc. v. Amneal Pharmaceuticals LLC, et al. Consolidated Case As previously disclosed, (i) Amgen appealed the Delaware District Court’s judgment of noninfringement of Amgen’s U.S. Patent No. 9,375,405 (the ’405 Patent) in favor of Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC (collectively, Amneal), and Piramal Healthcare UK Limited (Piramal), and (ii) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) appealed the Delaware District Court’s judgment of infringement by Zydus of Amgen’s ’405 Patent. On October 1, 2019, oral arguments for these appeals were held before the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court). - v. Cipla, et al. As previously disclosed, Amgen filed a motion requesting the Federal Circuit Court to vacate the Delaware District Court’s judgment of noninfringement of Amgen’s ’405 Patent with respect to Watson Laboratories, Inc. and Actavis Pharma, Inc. Cipla filed an opposition to this motion and moved to participate in the appeal as either an intervenor or as amicus curiae . On September 13, 2019, the Federal Circuit Court denied Amgen’s motion, lifted the stay of the briefing schedule which had been stayed pending disposition of Amgen’s motion to vacate, and granted Cipla permission to file a brief as amicus curiae . - v. Sun Pharmaceutical Industries Ltd., et al. On September 18, 2019, the Delaware District Court denied the motion filed by Sun Pharma Global FZE, Sun Pharmaceutical Industries, Ltd. and Sun Pharmaceutical Industries, Inc. (collectively, Sun), rejecting Sun’s contention that its settlement agreement with Amgen permitted Sun’s generic cinacalcet to enter the market without liability. Amgen Inc. v. The ACME Laboratories Ltd. On September 11, 2019, Amgen filed a lawsuit in the Delaware District Court against The ACME Laboratories Ltd. for infringement of Amgen’s ’405 Patent. Amgen Inc. v. Accord Healthcare, Inc. On October 21, 2019, based on a joint request of the parties, the Delaware District Court entered judgment of infringement and validity of Amgen’s ’405 Patent and an injunction prohibiting the manufacture, use, sale, offer to sell, or importation into the United States of Accord Healthcare, Inc.’s cinacalcet product during the term of the ’405 Patent unless specifically authorized pursuant to the confidential settlement agreement. Sensipar ® Antitrust Class Actions On July 31, 2019, the multidistrict litigation panel entered an order consolidating in the Delaware District Court the four class action lawsuits brought by plaintiffs on behalf of a putative class of direct or indirect purchasers of Sensipar ® against Amgen and various entities affiliated with Teva Pharmaceutical Industries Ltd. On September 13, 2019, the plaintiffs filed amended complaints, and on October 15, 2019, Amgen filed its motion to dismiss both the direct purchaser plaintiffs’ consolidated class action complaint and the indirect purchaser end payor plaintiffs’ complaint. Repatha ® (evolocumab) Patent Litigation Amgen Inc., et al. v. Sanofi, et al. On August 28, 2019, the Delaware District Court ruled on the post-trial motions by Sanofi, Sanofi-Aventis U.S. LLC, Aventisub LLC (formerly doing business as Aventis Pharmaceuticals Inc.) and Regeneron Pharmaceuticals, Inc., denying their request for a new trial and their request to reverse the jury verdict that U.S. Patent Nos. 8,829,165 (the ’165 Patent) and 8,859,741 (the ’741 Patent) provide written description support for the claimed inventions. The Delaware District Court also ruled as a matter of law that claims 19 and 29 of the ’165 Patent and claim 7 of the ’741 Patent are invalid for failing to meet the enablement requirement, overturning the jury verdict. On October 23, 2019, Amgen filed a notice of appeal to the Federal Circuit Court. Patent Disputes in the International Region The European Patent Office’s decision on November 30, 2018 confirming the validity of Amgen’s European Patent No. 2,215,124 has been appealed to the Technical Board of Appeal and a two-day hearing is scheduled to begin on March 24, 2020. We are also involved in and expect future involvement in additional disputes regarding our proprotein convertase subtilisin/kexin type 9 (PCSK9) patents in other jurisdictions and regions, including matters filed against us and that we have filed in the United Kingdom, Germany, France and Japan. ENBREL (etanercept) Patent Litigation Immunex Corporation, et al. v. Samsung Bioepis Co., Ltd. On August 5, 2019, defendant Samsung Bioepis Co., Ltd. responded to the complaint by Immunex Corporation (Immunex, a wholly-owned subsidiary of Amgen Inc.), Amgen Manufacturing, Limited (AML) and Hoffmann-La Roche Inc., denying infringement and seeking judgment that the patents-in-suit are invalid, unenforceable, and/or not infringed. Immunex Corporation, et al. v. Sandoz Inc., et al. On August 9, 2019, the U.S. District Court for the District of New Jersey (the New Jersey District Court) issued its decision upholding the validity of U.S. Patent Nos. 8,063,182 and 8,163,522. On October 8, 2019, by stipulation of Immunex and AML, and Sandoz Inc., Sandoz International GmbH and Sandoz GmbH (collectively, Sandoz), the New Jersey District Court entered final judgment and a permanent injunction prohibiting Sandoz from making, using, importing, selling or offering for sale Sandoz’s etanercept product, and, on the same day, Sandoz appealed the final judgment to the Federal Circuit Court. NEUPOGEN ® (filgrastim) / Neulasta ® (pegfilgrastim) Patent Litigation Amgen Inc., et al. v. Apotex Inc., et al. On August 27, 2019, the U.S. District Court for the Southern District of Florida granted an unopposed motion to substitute Accord BioPharma in place of defendants Apotex Inc. and Apotex Corp. In a separate challenge at the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB), on October 4, 2019, the PTAB granted judgment adverse to Apotex Biologics, LLC, Apotex Inc., and Apotex Corp. in post-grant review proceeding on Amgen’s U.S. Patent No. 9,856,287 (the ’287 Patent). The review proceedings continue with Kashiv Biosciences, LLC (Kashiv) as the sole petitioner. Amgen Inc., et al. v. Kashiv Biosciences, LLC, et al. On September 16, 2019, the New Jersey District Court entered Amgen and Kashiv’s stipulation to dismiss without prejudice the causes of action directed solely to U.S. Patent No. 8,952,138 (the ’138 Patent), in light of the PTAB’s May 20, 2019 amended final written decision finding that claim 18 of the ’138 Patent was obvious. In a separate challenge by Kashiv at the PTAB, on September 11, 2019, the PTAB instituted the inter partes review (IPR) of Amgen’s U.S. Patent Nos. 8,940,878 and 9,643,997 (the ‘997 Patent). Amgen Inc., et al. v. Mylan Inc., et al. The District Court for the Western District of Pennsylvania entered judgment of noninfringement of Amgen’s U.S. Patent No. 8,273,707 and the ’997 Patent on August 21, 2019, and September 17, 2019, respectively, based on a joint request of Amgen and Mylan Inc., Mylan Pharmaceuticals Inc., Mylan GmbH, and Mylan N.V., resolving the patent disputes that had been the subject of the lawsuit. Amgen Inc., et al. v. Sandoz Inc., et al. On September 3, 2019, the Federal Circuit Court denied Amgen’s petition for rehearing en banc in the consolidated appeal and reissued its opinion with amendment, but without disturbing its affirmance of grant of summary judgment of noninfringement in favor of Sandoz by the U.S. District Court for the Northern District of California. Amgen Inc., et al. v. Tanvex BioPharma USA, Inc., et al. On September 23, 2019, defendants Tanvex BioPharma USA, Inc., Tanvex BioPharma, Inc., and Tanvex Biologics Corporation responded to Amgen’s complaint, denying infringement and seeking judgment of noninfringement and invalidity of Amgen’s ’287 Patent. Fresenius PTAB Challenge On October 16, 2019, the PTAB denied the petition by Fresenius Kabi USA, LLC and Fresenius Kabi SwissBiosim GmbH to institute the IPR with respect to the patentability of Amgen’s ’287 Patent. Hospira EPOGEN ® (epoetin alfa) Patent Litigation Amgen Inc., et al. v. Hospira, Inc. On September 30, 2019, the Federal Circuit Court heard argument on the appeal by Hospira, Inc. (Hospira), a subsidiary of Pfizer, and the cross-appeal by Amgen and AML, of the Delaware District Court’s final judgment that Amgen’s U.S. Patent No. 5,856,298 is valid and infringed by Hospira, that Amgen’s U.S. Patent No. 5,756,349 is not infringed by Hospira, and awarding Amgen $70 million in damages for Hospira’s infringement. Litigation relating to our Biosimilar Products KANJINTI TM* (trastuzumab-anns) Patent Litigation Genentech, Inc. v. Amgen Inc. As previously disclosed, Genentech, Inc. (Genentech) appealed the Delaware District Court’s denial of Genentech’s motion for a preliminary injunction and requested the Federal Circuit Court to enter an injunction prohibiting Amgen from continuing with its launch of KANJINTI TM until final resolution of the appeal. On August 7, 2019, the Federal Circuit Court denied Genentech’s motion for an injunction pending appeal. On September 4, 2019, Genentech filed its third amended complaint adding a demand for a jury trial and an award of damages for infringement. On September 23, 2019, the Delaware District Court ordered a stipulated dismissal with prejudice of all claims for infringement of certain asserted patents, leaving four patents asserted by Genentech in the litigation. On September 24, 2019, Amgen filed its answer to Genentech’s third amended complaint denying infringement of any valid patent claim. On September 26, 2019, the Delaware District Court ordered that a 5-day jury trial on the patent issues commence on December 9, 2019, and the trial on damages (and therefore willfulness) be tried separately at a later date, if necessary. MVASI TM (bevacizumab-awwb) Patent Litigation Genentech, Inc. and City of Hope v. Immunex Rhode Island Corp. and Amgen Inc. On August 16, 2019, the Federal Circuit Court denied Genentech’s motion requesting the Federal Circuit Court enter an injunction prohibiting Amgen from marketing MVASI TM until final resolution of Genentech’s appeal. Genentech, Inc. and City of Hope v. Amgen Inc. On August 22, 2019 and October 29, 2019, by stipulation of the parties, the Delaware District Court entered judgment of noninfringement, in each instance, with respect to one of the patents asserted in the consolidated lawsuit, leaving a total of six remaining patents asserted by Genentech in the litigation. Humira ® Biosimilar Antitrust Class Actions As previously disclosed, twelve purported class actions against Amgen, along with AbbVie Inc. and AbbVie Biotechnology Ltd. were filed in the U.S. District Court for the Northern District of Illinois (the Illinois Northern District Court). On August 9, 2019, the plaintiffs filed their consolidated complaint in the Illinois Northern District Court. On October 11, 2019, the defendants filed a joint motion to dismiss the consolidated complaint (as well as brief individual motions), challenging the legal sufficiency of the plaintiffs’ allegations to state any claim for relief under the law. No argument date has been set and plaintiffs’ response to the motions is due on November 19, 2019.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Business	Business Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
Basis of presentation	Basis of presentation The financial information for the three and nine months ended September 30, 2019 and 2018 , is unaudited but includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year. The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2018 , and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2019 and June 30, 2019 .
Principles of consolidation	Principles of consolidation The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Property, plant and equipment, net	Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $8.2 billion and $7.8 billion as of September 30, 2019 and December 31, 2018 , respectively.
Leases	Leases Adoption of new lease standard In February 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that amends the guidance for the accounting and disclosure of leases. This new standard requires that lessees recognize the assets and liabilities that arise from leases on the balance sheet, including leases classified as operating leases, and that they disclose qualitative and quantitative information about leasing arrangements. The FASB subsequently issued additional amendments to address issues arising from the implementation of the new lease standard. We adopted this standard as of January 1, 2019, using the modified-retrospective method. This approach provides a method for recording existing leases at adoption. We used the adoption date as our date of initial application, and thus, comparative-period financial information is not presented for periods prior to the adoption date. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allowed us to carry forward the historical lease classification. Adoption of the new standard resulted in total lease liabilities of $510 million and right-of-use (ROU) assets of $439 million as of January 1, 2019. The difference between the initial lease liabilities and the ROU assets is related primarily to previously existing lease liabilities. The standard did not materially impact our Condensed Consolidated Statements of Income and had no impact on our Condensed Consolidated Statements of Cash Flows. Our accounting policies under the new standard are described below. See Note 9, Leases. Lease recognition At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating or financing. Operating leases are included in Other assets, Accrued liabilities and Other noncurrent liabilities in our Condensed Consolidated Balance Sheets. ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. Lease recognition occurs at the commencement date, and lease liability amounts are based on the present value of lease payments made during the lease term. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Because most of our leases do not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. We have lease agreements with both lease and nonlease components, which are generally accounted for together as a single lease component. In addition, for certain vehicle and equipment leases, we apply a portfolio approach to determine the lease term and discount rate.
Other recent accounting pronouncements	Other recent accounting pronouncements In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary-impairment model. The new standard is effective for interim and annual periods beginning on January 1, 2020. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. We have substantially completed our impact assessment and do not currently anticipate a material impact on our condensed consolidated financial statements.

Revenues (Tables)

Revenues (Tables)	9 Months Ended
	Sep. 30, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of revenue by product and by geographic area	Revenues were as follows (in millions): Three months ended September 30, 2019 2018 US ROW Total US ROW Total Enbrel ® (etanercept) $ 1,323 $ 43 $ 1,366 $ 1,242 $ 50 $ 1,292 Neulasta ® (pegfilgrastim) 619 92 711 897 154 1,051 Prolia ® (denosumab) 425 205 630 354 178 532 XGEVA ® (denosumab) 356 120 476 323 110 433 Aranesp ® (darbepoetin alfa) 204 248 452 248 229 477 KYPROLIS ® (carfilzomib) 163 103 266 142 90 232 EPOGEN ® (epoetin alfa) 215 — 215 252 — 252 Sensipar ® /Mimpara ® (cinacalcet) 38 71 109 330 79 409 Other products 686 552 1,238 472 360 832 Total product sales (1) $ 4,029 $ 1,434 5,463 $ 4,260 $ 1,250 5,510 Other revenues 274 394 Total revenues $ 5,737 $ 5,904 Nine months ended September 30, 2019 2018 US ROW Total US ROW Total ENBREL $ 3,744 $ 136 $ 3,880 $ 3,544 $ 155 $ 3,699 Neulasta ® 2,231 325 2,556 2,854 452 3,306 Prolia ® 1,273 647 1,920 1,070 566 1,636 XGEVA ® 1,091 355 1,446 994 336 1,330 Aranesp ® 578 724 1,302 714 689 1,403 KYPROLIS ® 483 295 778 430 287 717 EPOGEN ® 657 — 657 746 — 746 Sensipar ® /Mimpara ® 216 228 444 1,069 257 1,326 Other products 1,889 1,451 3,340 1,353 1,016 2,369 Total product sales (1) $ 12,162 $ 4,161 16,323 $ 12,774 $ 3,758 16,532 Other revenues 842 985 Total revenues $ 17,165 $ 17,517 ____________ (1) Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2019 and 2018 .

Earnings per share (Tables)

Earnings per share (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Computation for basic and diluted earnings per share	The computations for basic and diluted EPS were as follows (in millions, except per-share data): Three months ended Nine months ended 2019 2018 2019 2018 Income (Numerator): Net income for basic and diluted EPS $ 1,968 $ 1,859 $ 6,139 $ 6,466 Shares (Denominator): Weighted-average shares for basic EPS 599 645 609 669 Effect of dilutive securities 3 4 4 4 Weighted-average shares for diluted EPS 602 649 613 673 Basic EPS $ 3.29 $ 2.88 $ 10.08 $ 9.67 Diluted EPS $ 3.27 $ 2.86 $ 10.01 $ 9.61

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2019
Investments, Debt and Equity Securities [Abstract]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions): Types of securities as of September 30, 2019 Amortized cost Gross unrealized gains Gross unrealized losses Fair values U.S. Treasury notes $ 1,164 $ 3 $ — $ 1,167 U.S. Treasury bills 2,494 — — 2,494 Other government-related debt securities: U.S. — — — — Foreign and other 896 29 — 925 Corporate debt securities: Financial 2,116 24 — 2,140 Industrial 2,002 23 — 2,025 Other 531 6 — 537 Residential-mortgage-backed securities 512 4 — 516 Other mortgage- and asset-backed securities 43 — — 43 Money market mutual funds 8,017 — — 8,017 Other short-term interest-bearing securities 2,363 — — 2,363 Total interest-bearing securities $ 20,138 $ 89 $ — $ 20,227 Types of securities as of December 31, 2018 Amortized cost Gross unrealized gains Gross unrealized losses Fair values U.S. Treasury notes $ 2,710 $ — $ (47 ) $ 2,663 U.S. Treasury bills 8,191 — — 8,191 Other government-related debt securities: U.S. 112 — (2 ) 110 Foreign and other 972 1 (41 ) 932 Corporate debt securities: Financial 2,778 — (81 ) 2,697 Industrial 2,603 — (99 ) 2,504 Other 583 — (21 ) 562 Residential-mortgage-backed securities 1,458 — (36 ) 1,422 Other mortgage- and asset-backed securities 483 — (14 ) 469 Money market mutual funds 5,659 — — 5,659 Other short-term interest-bearing securities 3,515 — — 3,515 Total interest-bearing securities $ 29,064 $ 1 $ (341 ) $ 28,724
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets	The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions): Condensed Consolidated Balance Sheets locations September 30, December 31, Cash and cash equivalents $ 10,789 $ 6,365 Marketable securities 9,438 22,359 Total interest-bearing securities $ 20,227 $ 28,724
Fair values of available-for-sale interest-bearing security investments by contractual maturity	The fair values of interest-bearing securities by contractual maturity, except for mortgage- and asset-backed securities that do not have a single maturity date, were as follows (in millions): Contractual maturities September 30, December 31, Maturing in one year or less $ 12,941 $ 17,424 Maturing after one year through three years 4,855 3,356 Maturing after three years through five years 1,226 5,168 Maturing after five years through ten years 646 885 Mortgage- and asset-backed securities 559 1,891 Total interest-bearing securities $ 20,227 $ 28,724
Available-for-sale securities, continuous unrealized loss position, fair value	As of December 31, 2018, the fair values and gross unrealized losses of interest-bearing securities in an unrealized loss position aggregated by type and length of time that the securities have been in a continuous loss position were as follows (in millions): Less than 12 months 12 months or more Types of securities as of December 31, 2018 Fair values Unrealized losses Fair values Unrealized losses U.S. Treasury notes $ 1,219 $ (21 ) $ 1,444 $ (26 ) Other government-related debt securities: U.S. — — 110 (2 ) Foreign and other 631 (31 ) 240 (10 ) Corporate debt securities: Financial 1,968 (59 ) 718 (22 ) Industrial 1,898 (81 ) 529 (18 ) Other 529 (20 ) 28 (1 ) Residential-mortgage-backed securities 576 (14 ) 840 (22 ) Other mortgage- and asset-backed securities 17 — 451 (14 ) Total $ 6,838 $ (226 ) $ 4,360 $ (115 )

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories consisted of the following (in millions): September 30, December 31, Raw materials $ 324 $ 257 Work in process 1,923 1,660 Finished goods 996 1,023 Total inventories $ 3,243 $ 2,940

Goodwill and other intangible_2

Goodwill and other intangible assets (Tables)	9 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill	The change in the carrying amount of goodwill was as follows (in millions): Nine months ended Beginning balance $ 14,699 Addition from Nuevolution acquisition 26 Currency translation adjustment (20 ) Ending balance $ 14,705
Schedule of identifiable intangible assets	Other intangible assets consisted of the following (in millions): September 30, 2019 December 31, 2018 Gross carrying amounts Accumulated amortization Other intangible assets, net Gross carrying amounts Accumulated amortization Other intangible assets, net Finite-lived intangible assets: Developed-product-technology rights $ 12,548 $ (7,978 ) $ 4,570 $ 12,573 $ (7,479 ) $ 5,094 Licensing rights 3,761 (2,286 ) 1,475 3,772 (2,032 ) 1,740 Marketing-related rights 1,209 (972 ) 237 1,297 (1,019 ) 278 Research and development technology rights 1,266 (922 ) 344 1,148 (872 ) 276 Total finite-lived intangible assets 18,784 (12,158 ) 6,626 18,790 (11,402 ) 7,388 Indefinite-lived intangible assets: In-process research and development 76 — 76 55 — 55 Total other intangible assets $ 18,860 $ (12,158 ) $ 6,702 $ 18,845 $ (11,402 ) $ 7,443

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Summary information, components of lease costs and cash and noncash information on leases	Cash and noncash information related to our leases was as follows (in millions): Three months ended September 30, 2019 Nine months ended Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 42 $ 115 ROU assets obtained in exchange for lease obligations: Operating leases $ 29 $ 83 The following table summarizes information related to our leases, all of which are classified as operating, included in our Condensed Consolidated Balance Sheets (in millions): Condensed Consolidated Balance Sheets locations September 30, 2019 Assets: Other assets $ 422 Liabilities: Accrued liabilities $ 135 Other noncurrent liabilities 351 Total lease liabilities $ 486 The components of net lease costs were as follows (in millions): Lease costs Three months ended September 30, 2019 Nine months ended Operating (1) $ 50 $ 149 Sublease income (8 ) (25 ) Total net lease costs $ 42 $ 124 ____________ (1) Includes short-term leases and variable lease costs, which were not material for the three and nine months ended September 30, 2019 .
Maturities of lease liabilities	Maturities of lease liabilities as of September 30, 2019 , were as follows (in millions): Maturity dates Operating leases Remaining three months ending December 31, 2019 $ 31 2020 157 2021 137 2022 77 2023 65 Thereafter 55 Total lease payments (1) 522 Less imputed interest (36 ) Present value of lease liabilities $ 486 ____________ (1) Includes future rental commitments for abandoned leases of $189 million . We expect to receive total future rental income of $149 million related to noncancelable subleases for abandoned facilities.

Financing arrangements (Tables)

Financing arrangements (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of borrowings	Our borrowings consisted of the following (in millions): September 30, December 31, 5.70% notes due 2019 (5.70% 2019 Notes) $ — $ 1,000 1.90% notes due 2019 (1.90% 2019 Notes) — 700 Floating Rate Notes due 2019 — 550 2.20% notes due 2019 (2.20% 2019 Notes) — 1,400 2.125% €675 million notes due 2019 (2.125% 2019 euro Notes) — 774 4.50% notes due 2020 (4.50% 2020 Notes) 300 300 2.125% notes due 2020 (2.125% 2020 Notes) 750 750 Floating Rate Notes due 2020 300 300 2.20% notes due 2020 (2.20% 2020 Notes) 700 700 3.45% notes due 2020 (3.45% 2020 Notes) 900 900 4.10% notes due 2021 (4.10% 2021 Notes) 1,000 1,000 1.85% notes due 2021 (1.85% 2021 Notes) 750 750 3.875% notes due 2021 (3.875% 2021 Notes) 1,750 1,750 1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) 1,362 1,433 2.70% notes due 2022 (2.70% 2022 Notes) 500 500 2.65% notes due 2022 (2.65% 2022 Notes) 1,500 1,500 3.625% notes due 2022 (3.625% 2022 Notes) 750 750 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) 702 713 2.25% notes due 2023 (2.25% 2023 Notes) 750 750 3.625% notes due 2024 (3.625% 2024 Notes) 1,400 1,400 3.125% notes due 2025 (3.125% 2025 Notes) 1,000 1,000 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) 817 860 2.60% notes due 2026 (2.60% 2026 Notes) 1,250 1,250 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) 584 606 3.20% notes due 2027 (3.20% 2027 Notes) 1,000 1,000 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) 860 893 6.375% notes due 2037 (6.375% 2037 Notes) 552 552 6.90% notes due 2038 (6.90% 2038 Notes) 291 291 6.40% notes due 2039 (6.40% 2039 Notes) 466 466 5.75% notes due 2040 (5.75% 2040 Notes) 412 412 4.95% notes due 2041 (4.95% 2041 Notes) 600 600 5.15% notes due 2041 (5.15% 2041 Notes) 974 974 5.65% notes due 2042 (5.65% 2042 Notes) 487 487 5.375% notes due 2043 (5.375% 2043 Notes) 261 261 4.40% notes due 2045 (4.40% 2045 Notes) 2,250 2,250 4.563% notes due 2048 (4.563% 2048 Notes) 1,415 1,415 4.663% notes due 2051 (4.663% 2051 Notes) 3,541 3,541 Other notes due 2097 100 100 Unamortized bond discounts, premiums and issuance costs, net (874 ) (896 ) Fair value adjustments 391 (53 ) Total carrying value of debt 29,791 33,929 Less current portion (2,049 ) (4,419 ) Total long-term debt $ 27,742 $ 29,510

Stockholders' equity (Tables)

Stockholders' equity (Tables)	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Summary of activity under our stock repurchase program	Activity under our stock repurchase program, on a trade date basis, was as follows (in millions): 2019 2018 Shares Dollars Shares * Dollars First quarter 15.9 $ 3,031 56.4 $ 10,787 Second quarter 13.1 2,349 18.2 3,190 Third quarter 6.2 1,170 8.7 1,713 Total stock repurchases 35.2 $ 6,550 83.4 $ 15,690
Components of accumulated other comprehensive income	The components of Accumulated other comprehensive income (loss) (AOCI) were as follows (in millions): Foreign currency translation Cash flow hedges Available-for-sale securities Other AOCI Balance as of December 31, 2018 $ (670 ) $ 241 $ (338 ) $ (2 ) $ (769 ) Foreign currency translation adjustments (13 ) — — — (13 ) Unrealized gains — 30 218 — 248 Reclassification adjustments to income — 28 4 — 32 Income taxes — (13 ) (1 ) — (14 ) Balance as of March 31, 2019 (683 ) 286 (117 ) (2 ) (516 ) Foreign currency translation adjustments (4 ) — — — (4 ) Unrealized (losses) gains — (96 ) 161 — 65 Reclassification adjustments to income — (36 ) 2 — (34 ) Other — — — 6 6 Income taxes — 28 (10 ) — 18 Balance as of June 30, 2019 (687 ) 182 36 4 (465 ) Foreign currency translation adjustments (39 ) — — — (39 ) Unrealized gains — 71 35 — 106 Reclassification adjustments to income — 38 3 — 41 Income taxes — (23 ) (8 ) — (31 ) Balance as of September 30, 2019 $ (726 ) $ 268 $ 66 $ 4 $ (388 )
Reclassifications out of accumulated other comprehensive income	Reclassifications out of AOCI and into earnings were as follows (in millions): Three months ended September 30, Components of AOCI 2019 2018 Condensed Consolidated Statements of Income locations Cash flow hedges: Foreign currency contract gains $ 26 $ 3 Product sales Cross-currency swap contract losses (64 ) (36 ) Interest and other income, net (38 ) (33 ) Income before income taxes 8 7 Provision for income taxes $ (30 ) $ (26 ) Net income Available-for-sale securities: Net realized losses $ (3 ) $ (103 ) Interest and other income, net — 1 Provision for income taxes $ (3 ) $ (102 ) Net income Nine months ended September 30, Components of AOCI 2019 2018 Condensed Consolidated Statements of Income locations Cash flow hedges: Foreign currency contract gains (losses) $ 62 $ (51 ) Product sales Cross-currency swap contract losses (92 ) (170 ) Interest and other income, net (30 ) (221 ) Income before income taxes 6 47 Provision for income taxes $ (24 ) $ (174 ) Net income Available-for-sale securities: Net realized losses $ (9 ) $ (352 ) Interest and other income, net — 3 Provision for income taxes $ (9 ) $ (349 ) Net income

Fair value measurement (Tables)

Fair value measurement (Tables)	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis	The fair values of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions): Quoted prices in Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Fair value measurement as of September 30, 2019, using: Total Assets: Interest-bearing securities: U.S. Treasury notes $ 1,167 $ — $ — $ 1,167 U.S. Treasury bills 2,494 — — 2,494 Other government-related debt securities: U.S. — — — — Foreign and other — 925 — 925 Corporate debt securities: Financial — 2,140 — 2,140 Industrial — 2,025 — 2,025 Other — 537 — 537 Residential-mortgage-backed securities — 516 — 516 Other mortgage- and asset-backed securities — 43 — 43 Money market mutual funds 8,017 — — 8,017 Other short-term interest-bearing securities — 2,363 — 2,363 Equity securities 277 — — 277 Derivatives: Foreign currency contracts — 339 — 339 Cross-currency swap contracts — 12 — 12 Interest rate swap contracts — 354 — 354 Total assets $ 11,955 $ 9,254 $ — $ 21,209 Liabilities: Derivatives: Foreign currency contracts $ — $ 6 $ — $ 6 Cross-currency swap contracts — 478 — 478 Contingent consideration obligations — — 62 62 Total liabilities $ — $ 484 $ 62 $ 546 Quoted prices in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Fair value measurement as of December 31, 2018, using: Total Assets: Interest-bearing securities: U.S. Treasury notes $ 2,663 $ — $ — $ 2,663 U.S. Treasury bills 8,191 — — 8,191 Other government-related debt securities: U.S. — 110 — 110 Foreign and other — 932 — 932 Corporate debt securities: Financial — 2,697 — 2,697 Industrial — 2,504 — 2,504 Other — 562 — 562 Residential-mortgage-backed securities — 1,422 — 1,422 Other mortgage- and asset-backed securities — 469 — 469 Money market mutual funds 5,659 — — 5,659 Other short-term interest-bearing securities — 3,515 — 3,515 Equity securities 176 — — 176 Derivatives: Foreign currency contracts — 182 — 182 Cross-currency swap contracts — 170 — 170 Interest rate swap contracts — 56 — 56 Total assets $ 16,689 $ 12,619 $ — $ 29,308 Liabilities: Derivatives: Foreign currency contracts $ — $ 26 $ — $ 26 Cross-currency swap contracts — 401 — 401 Interest rate swap contracts — 149 — 149 Contingent consideration obligations — — 72 72 Total liabilities $ — $ 576 $ 72 $ 648

Derivative instruments (Tables)

Derivative instruments (Tables)	9 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of notional amounts and interest rates for cross-currency swaps	The notional amounts and interest rates of our cross-currency swaps as of September 30, 2019 , were as follows (notional amounts in millions): Foreign currency U.S. dollars Hedged notes Notional amounts Interest rates Notional amounts Interest rates 1.25% 2022 euro Notes € 1,250 1.3 % $ 1,388 3.2 % 0.41% 2023 Swiss franc Bonds CHF 700 0.4 % $ 704 3.4 % 2.00% 2026 euro Notes € 750 2.0 % $ 833 3.9 % 5.50% 2026 pound sterling Notes £ 475 5.5 % $ 747 6.0 % 4.00% 2029 pound sterling Notes £ 700 4.0 % $ 1,111 4.5 %
Unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges	The unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions): Three months ended Nine months ended Derivatives in cash flow hedging relationships 2019 2018 2019 2018 Foreign currency contracts $ 176 $ 41 $ 245 $ 233 Cross-currency swap contracts (105 ) (22 ) (240 ) (99 ) Total unrealized gains $ 71 $ 19 $ 5 $ 134
Derivatives in fair value hedging relationships	The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions): Carrying amounts of hedged liabilities (1) Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities (2) Condensed Consolidated Balance Sheets locations September 30, 2019 December 31, 2018 September 30, 2019 December 31, 2018 Current portion of long-term debt $ — $ 2,396 $ — $ (3 ) Long-term debt $ 9,811 $ 9,361 $ 391 $ (50 ) ____________ (1) Current portion of long-term debt includes $1.0 billion of carrying value with discontinued hedging relationships as of December 31, 2018 . Long-term debt includes $136 million and $137 million of carrying value with discontinued hedging relationships as of September 30, 2019 and December 31, 2018 , respectively. (2) Current portion of long-term debt includes $3 million of hedging adjustments on discontinued hedging relationships as of December 31, 2018. Long-term debt includes $36 million and $37 million of hedging adjustments on discontinued hedging relationships as of September 30, 2019 and December 31, 2018 , respectively.
Summary of amounts of income and expense line items	The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions): Three months ended September 30, 2019 Nine months ended September 30, 2019 Product sales Interest and other income, net Interest (expense), net Product sales Interest and other income, net Interest (expense), net Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income $ 5,463 $ 114 $ (313 ) $ 16,323 $ 517 $ (988 ) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ 26 $ — $ — $ 62 $ — $ — Cross-currency swap contracts $ — $ (64 ) $ — $ — $ (92 ) $ — (Losses) gains on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ (96 ) $ — $ — $ (444 ) Derivatives designated as hedging instruments $ — $ — $ 96 $ — $ — $ 447 Three months ended September 30, 2018 Nine months ended September 30, 2018 Product sales Interest and other income, net Interest (expense), net Product sales Interest and other income, net Interest (expense), net Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income $ 5,510 $ 126 $ (355 ) $ 16,532 $ 519 $ (1,040 ) The effects of cash flow and fair value hedging: Gains (losses) on cash flow hedging relationships reclassified out of AOCI: Foreign currency contracts $ 3 $ — $ — $ (51 ) $ — $ — Cross-currency swap contracts $ — $ (36 ) $ — $ — $ (170 ) $ — Gains (losses) on fair value hedging relationships—interest rate swap agreements: Hedged items (1) $ — $ — $ 48 $ — $ — $ 278 Derivatives designated as hedging instruments $ — $ — $ (44 ) $ — $ — $ (259 ) __________ (1) Gains (losses) on hedged items do not completely offset (losses) gains on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships.
Fair values of derivatives included in the Condensed Consolidated Balance Sheets	The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions): Derivative assets Derivative liabilities September 30, 2019 Condensed Consolidated Balance Sheets locations Fair values Condensed Consolidated Balance Sheets locations Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other assets $ 339 Accrued liabilities/ Other noncurrent liabilities $ 6 Cross-currency swap contracts Other current assets/ Other assets 12 Accrued liabilities/ Other noncurrent liabilities 478 Interest rate swap contracts Other current assets/ Other assets 354 Accrued liabilities/ Other noncurrent liabilities — Total derivatives designated as hedging instruments 705 484 Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets — Accrued liabilities — Total derivatives not designated as hedging instruments — — Total derivatives $ 705 $ 484 Derivative assets Derivative liabilities December 31, 2018 Condensed Consolidated Balance Sheets locations Fair values Condensed Consolidated Balance Sheets locations Fair values Derivatives designated as hedging instruments: Foreign currency contracts Other current assets/ Other assets $ 181 Accrued liabilities/ Other noncurrent liabilities $ 26 Cross-currency swap contracts Other current assets/ Other assets 170 Accrued liabilities/ Other noncurrent liabilities 401 Interest rate swap contracts Other current assets/ Other assets 56 Accrued liabilities/ Other noncurrent liabilities 149 Total derivatives designated as hedging instruments 407 576 Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets 1 Accrued liabilities — Total derivatives not designated as hedging instruments 1 — Total derivatives $ 408 $ 576

Summary of significant accoun_3

Summary of significant accounting policies (Details) $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)segment	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
Accounting Policies [Abstract]
Number of operating segments | segment	1
Accumulated depreciation and amortization on property, plant and equipment	$ 8,200		$ 7,800
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Lease liabilities	486
ROU asset	$ 422
New Lease Standard
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Lease liabilities		$ 510
ROU asset		$ 439

Business combinations (Details

Business combinations (Details Textual) - USD ($) $ in Millions	Aug. 25, 2019	Jul. 15, 2019	Sep. 30, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Goodwill			$ 14,705	$ 14,699
Nuevolution
Business Acquisition [Line Items]
Business Combination, Consideration Transferred		$ 183
Goodwill		26
Fair value of liabilities assumed, deferred tax liabilities		22
Fair value of assets acquired and liabilities assumed, net other assets and liabilities		29
Nuevolution | R & D Technology rights
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired		$ 150
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life		10 years
Celgene
Business Acquisition [Line Items]
Business Combination, Consideration Transferred	$ 13,400

Revenues (Details)

Revenues (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)segment	Sep. 30, 2018USD ($)
Revenue from Contract with Customer [Abstract]
Number of operating segments | segment			1
Revenue from External Customer [Line Items]
Total revenues	$ 5,737	$ 5,904	$ 17,165	$ 17,517
Product sales [Member]
Revenue from External Customer [Line Items]
Total product sales	5,463	5,510	16,323	16,532
Product sales [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	4,029	4,260	12,162	12,774
Product sales [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	1,434	1,250	4,161	3,758
Enbrel® (etanercept) [Member]
Revenue from External Customer [Line Items]
Total product sales	1,366	1,292	3,880	3,699
Enbrel® (etanercept) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	1,323	1,242	3,744	3,544
Enbrel® (etanercept) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	43	50	136	155
Neulasta® (pegfilgrastim) [Member]
Revenue from External Customer [Line Items]
Total product sales	711	1,051	2,556	3,306
Neulasta® (pegfilgrastim) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	619	897	2,231	2,854
Neulasta® (pegfilgrastim) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	92	154	325	452
Prolia® (denosumab) [Member]
Revenue from External Customer [Line Items]
Total product sales	630	532	1,920	1,636
Prolia® (denosumab) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	425	354	1,273	1,070
Prolia® (denosumab) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	205	178	647	566
XGEVA® (denosumab) [Member]
Revenue from External Customer [Line Items]
Total product sales	476	433	1,446	1,330
XGEVA® (denosumab) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	356	323	1,091	994
XGEVA® (denosumab) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	120	110	355	336
Aranesp® (darbepoetin alfa) [Member]
Revenue from External Customer [Line Items]
Total product sales	452	477	1,302	1,403
Aranesp® (darbepoetin alfa) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	204	248	578	714
Aranesp® (darbepoetin alfa) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	248	229	724	689
KYPROLIS® (carfilzomib) [Member]
Revenue from External Customer [Line Items]
Total product sales	266	232	778	717
KYPROLIS® (carfilzomib) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	163	142	483	430
KYPROLIS® (carfilzomib) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	103	90	295	287
EPOGEN® (epoetin alfa) [Member]
Revenue from External Customer [Line Items]
Total product sales	215	252	657	746
EPOGEN® (epoetin alfa) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	215	252	657	746
EPOGEN® (epoetin alfa) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	0	0	0	0
Sensipar® / Mimpara® (cinacalcet) [Member]
Revenue from External Customer [Line Items]
Total product sales	109	409	444	1,326
Sensipar® / Mimpara® (cinacalcet) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	38	330	216	1,069
Sensipar® / Mimpara® (cinacalcet) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	71	79	228	257
Other products [Member]
Revenue from External Customer [Line Items]
Total product sales	1,238	832	3,340	2,369
Other products [Member] | US [Member]
Revenue from External Customer [Line Items]
Total product sales	686	472	1,889	1,353
Other products [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total product sales	552	360	1,451	1,016
Other revenues [Member]
Revenue from External Customer [Line Items]
Total revenues	$ 274	$ 394	$ 842	$ 985

Income taxes (Details)

Income taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Effective income tax rate	13.60%	11.20%	14.20%	12.10%
Increase in unrecognized tax benefits resulting from tax positions taken during the current period	$ 50		$ 160

Earnings per share (Details)

Earnings per share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Income (Numerator):
Net income for basic and diluted EPS	$ 1,968	$ 2,179	$ 1,992	$ 1,859	$ 2,296	$ 2,311	$ 6,139	$ 6,466
Shares (Denominator):
Weighted-average shares for basic EPS (in shares)	599			645			609	669
Effect of dilutive securities (in shares)	3			4			4	4
Weighted-average shares for diluted EPS (in shares)	602			649			613	673
Basic EPS (in usd per share)	$ 3.29			$ 2.88			$ 10.08	$ 9.67
Diluted EPS (in usd per share)	$ 3.27			$ 2.86			$ 10.01	$ 9.61

Investments (Details)

Investments (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]
Sale of securities receivable	$ 1,100
Amortized cost	20,138	$ 29,064
Gross unrealized gains	89	1
Gross unrealized losses	0	(341)
Fair values	20,227	28,724
U.S. Treasury notes [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	1,164	2,710
Gross unrealized gains	3	0
Gross unrealized losses	0	(47)
Fair values	1,167	2,663
U.S. Treasury bills [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	2,494	8,191
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	2,494	8,191
Other government-related debt securities - U.S. [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	0	112
Gross unrealized gains	0	0
Gross unrealized losses	0	(2)
Fair values	0	110
Other government-related debt securities - Foreign and other [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	896	972
Gross unrealized gains	29	1
Gross unrealized losses	0	(41)
Fair values	925	932
Corporate debt securities - Financial [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	2,116	2,778
Gross unrealized gains	24	0
Gross unrealized losses	0	(81)
Fair values	2,140	2,697
Corporate debt securities - Industrial [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	2,002	2,603
Gross unrealized gains	23	0
Gross unrealized losses	0	(99)
Fair values	2,025	2,504
Corporate debt securities - Other [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	531	583
Gross unrealized gains	6	0
Gross unrealized losses	0	(21)
Fair values	537	562
Residential mortgage-backed securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	512	1,458
Gross unrealized gains	4	0
Gross unrealized losses	0	(36)
Fair values	516	1,422
Other mortgage- and asset-backed securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	43	483
Gross unrealized gains	0	0
Gross unrealized losses	0	(14)
Fair values	43	469
Money market mutual funds [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	8,017	5,659
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	8,017	5,659
Other short-term interest-bearing securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized cost	2,363	3,515
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Fair values	$ 2,363	$ 3,515

Investments (Fair Values by Cla

Investments (Fair Values by Classification) (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
Cash and cash equivalents	$ 11,415	$ 6,945
Marketable securities	9,438	22,359
Total interest-bearing securities	20,227	28,724
Available-for-sale investments [Member]
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
Cash and cash equivalents	10,789	6,365
Marketable securities	9,438	22,359
Total interest-bearing securities	$ 20,227	$ 28,724

Investments (Available-for-sale

Investments (Available-for-sale Investments) (Details Textual) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]
Cash and cash equivalents	$ 626		$ 626		$ 580
Total realized gains	21	$ 5	23	$ 27
Total realized losses	$ 24	$ 108	$ 32	$ 379

Investments (Fair Values by Con

Investments (Fair Values by Contractual Maturity) (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]
Maturing in one year or less	$ 12,941	$ 17,424
Maturing after one year through three years	4,855	3,356
Maturing after three years through five years	1,226	5,168
Maturing after five years through ten years	646	885
Mortgage- and asset-backed securities	559	1,891
Total interest-bearing securities	$ 20,227	$ 28,724

Investments (Unrealized Losses

Investments (Unrealized Losses and Fair Values) (Details) $ in Millions	Dec. 31, 2018USD ($)
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	$ 6,838
Less than 12 months, Unrealized losses	(226)
12 months or more, Fair values	4,360
12 months or more, Unrealized losses	(115)
U.S. Treasury notes [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	1,219
Less than 12 months, Unrealized losses	(21)
12 months or more, Fair values	1,444
12 months or more, Unrealized losses	(26)
Other government-related debt securities - U.S. [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	0
Less than 12 months, Unrealized losses	0
12 months or more, Fair values	110
12 months or more, Unrealized losses	(2)
Other government-related debt securities - Foreign and other [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	631
Less than 12 months, Unrealized losses	(31)
12 months or more, Fair values	240
12 months or more, Unrealized losses	(10)
Corporate debt securities - Financial [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	1,968
Less than 12 months, Unrealized losses	(59)
12 months or more, Fair values	718
12 months or more, Unrealized losses	(22)
Corporate debt securities - Industrial [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	1,898
Less than 12 months, Unrealized losses	(81)
12 months or more, Fair values	529
12 months or more, Unrealized losses	(18)
Corporate debt securities - Other [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	529
Less than 12 months, Unrealized losses	(20)
12 months or more, Fair values	28
12 months or more, Unrealized losses	(1)
Residential mortgage-backed securities [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	576
Less than 12 months, Unrealized losses	(14)
12 months or more, Fair values	840
12 months or more, Unrealized losses	(22)
Other mortgage- and asset-backed securities [Member]
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair values	17
Less than 12 months, Unrealized losses	0
12 months or more, Fair values	451
12 months or more, Unrealized losses	$ (14)

Investments (Equity Securities)

Investments (Equity Securities) (Details Textual) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]
Equity securities	$ 277	$ 176
Equity securities without readily determinable fair value	$ 170	$ 222

Investments Investments (Limite

Investments Investments (Limited Partnership Investments) (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Limited Partnership [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Net Investment Income [Line Items]
Investments	$ 319	$ 285

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 324	$ 257
Work in process	1,923	1,660
Finished goods	996	1,023
Total inventories	$ 3,243	$ 2,940

Goodwill and other intangible_3

Goodwill and other intangible assets (Goodwill Roll Forward) (Details) $ in Millions	9 Months Ended
	Sep. 30, 2019USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 14,699
Addition from Nuevolution acquisition	26
Currency translation adjustment	(20)
Ending balance	$ 14,705

Goodwill and other intangible_4

Goodwill and other intangible assets (Identifiable Intangible Assets) (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	$ 18,784	$ 18,790
Accumulated amortization	(12,158)	(11,402)
Other intangible assets, net	6,626	7,388
Gross carrying amount	18,860	18,845
Accumulated amortization	(12,158)	(11,402)
Intangible assets, net	6,702	7,443
In-process Research and Development
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	76	55
Developed-Product-Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	12,548	12,573
Accumulated amortization	(7,978)	(7,479)
Other intangible assets, net	4,570	5,094
Licensing Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	3,761	3,772
Accumulated amortization	(2,286)	(2,032)
Other intangible assets, net	1,475	1,740
Marketing-Related Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	1,209	1,297
Accumulated amortization	(972)	(1,019)
Other intangible assets, net	237	278
Research and Development Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amounts	1,266	1,148
Accumulated amortization	(922)	(872)
Other intangible assets, net	$ 344	$ 276

Goodwill and other intangible_5

Goodwill and other intangible assets (Details Textual) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization charges associated with finite-lived intangible assets	$ 318	$ 331	$ 948	$ 983
Total estimated amortization of finite-lived intangible assets for the three months ending December 31, 2019	300		300
Total estimated amortization of finite-lived intangible assets for 2020	1,200		1,200
Total estimated amortization of finite-lived intangible assets for 2021	1,000		1,000
Total estimated amortization of finite-lived intangible assets for 2022	900		900
Total estimated amortization of finite-lived intangible assets for 2023	900		900
Total estimated amortization of finite-lived intangible assets for 2024	$ 900		$ 900

Leases (Textual) (Details)

Leases (Textual) (Details)	Sep. 30, 2019
Leases [Abstract]
Renewal term	7 years
Weighted-average remaining lease term (in years)	4 years
Weighted-average discount rate	3.31%

Leases (Summary of Leases) (Det

Leases (Summary of Leases) (Details) $ in Millions	Sep. 30, 2019USD ($)
Assets:
Other assets	$ 422
Liabilities:
Accrued liabilities	135
Other noncurrent liabilities	351
Total lease liabilities	$ 486

Leases (Components of Lease Cos

Leases (Components of Lease Costs) (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Leases [Abstract]
Operating	$ 50	$ 149
Sublease income	(8)	(25)
Total net lease costs	$ 42	$ 124

Leases (Maturities of Lease Lia

Leases (Maturities of Lease Liabilities) (Details) $ in Millions	Sep. 30, 2019USD ($)
Lessee, Lease, Description [Line Items]
Remaining three months ending December 31, 2019	$ 31
2020	157
2021	137
2022	77
2023	65
Thereafter	55
Total lease payments	522
Less imputed interest	(36)
Total lease liabilities	486
Abandoned Leases [Member]
Lessee, Lease, Description [Line Items]
Total lease payments	189
Expected total future rental income to be received	$ 149

Leases (Cash and Noncash Inform

Leases (Cash and Noncash Information of Leases) (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 42	$ 115
ROU assets obtained in exchange for lease obligations	$ 29	$ 83

Financing arrangements (Princip

Financing arrangements (Principal Amounts and Carrying Value of Long-term Borrowings) (Details) $ in Millions	Sep. 30, 2019USD ($)	Sep. 30, 2019EUR (€)	Sep. 30, 2019CHF (SFr)	Sep. 30, 2019GBP (£)	Dec. 31, 2018USD ($)
Debt Instrument [Line Items]
Unamortized bond discounts, premiums and issuance costs, net	$ (874)				$ (896)
Fair value adjustments	391				(53)
Total carrying value of debt	29,791				33,929
Less current portion	(2,049)				(4,419)
Total long-term debt	$ 27,742				29,510
Notes [Member] | 5.70% notes due 2019 (5.70% 2019 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross					1,000
Interest rate, stated percentage	5.70%	5.70%	5.70%	5.70%
Notes [Member] | 1.90% notes due 2019 (1.90% 2019 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 0				700
Interest rate, stated percentage	1.90%	1.90%	1.90%	1.90%
Notes [Member] | Floating Rate Notes due 2019 [Member]
Debt Instrument [Line Items]
Long-term debt, gross					550
Notes [Member] | 2.20% notes due 2019 (2.20% 2019 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross					1,400
Interest rate, stated percentage	2.20%	2.20%	2.20%	2.20%
Notes [Member] | 2.125% €675 million notes due 2019 (2.125% 2019 euro Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross					774
Face amount | €		€ 675,000,000
Interest rate, stated percentage	2.125%	2.125%	2.125%	2.125%
Notes [Member] | 4.50% notes due 2020 (4.50% 2020 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 300				300
Interest rate, stated percentage	4.50%	4.50%	4.50%	4.50%
Notes [Member] | 2.125% notes due 2020 (2.125% 2020 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 750				750
Interest rate, stated percentage	2.125%	2.125%	2.125%	2.125%
Notes [Member] | Floating Rate Notes Due 2020 [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 300				300
Notes [Member] | 2.20% notes due 2020 (2.20% 2020 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 700				700
Interest rate, stated percentage	2.20%	2.20%	2.20%	2.20%
Notes [Member] | 3.45% notes due 2020 (3.45% 2020 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 900				900
Interest rate, stated percentage	3.45%	3.45%	3.45%	3.45%
Notes [Member] | 4.10% notes due 2021 (4.10% 2021 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,000				1,000
Interest rate, stated percentage	4.10%	4.10%	4.10%	4.10%
Notes [Member] | 1.85% notes due 2021 (1.85% 2021 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 750				750
Interest rate, stated percentage	1.85%	1.85%	1.85%	1.85%
Notes [Member] | 3.875% notes due 2021 (3.875% 2021 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,750				1,750
Interest rate, stated percentage	3.875%	3.875%	3.875%	3.875%
Notes [Member] | 1.25% €1,250 million notes due 2022 (1.25% 2022 euro Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,362				1,433
Face amount | €		€ 1,250,000,000
Interest rate, stated percentage	1.25%	1.25%	1.25%	1.25%
Notes [Member] | 2.70% notes due 2022 (2.70% 2022 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 500				500
Interest rate, stated percentage	2.70%	2.70%	2.70%	2.70%
Notes [Member] | 2.65% notes due 2022 (2.65% 2022 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,500				1,500
Interest rate, stated percentage	2.65%	2.65%	2.65%	2.65%
Notes [Member] | 3.625% notes due 2022 (3.625% 2022 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 750				750
Interest rate, stated percentage	3.625%	3.625%	3.625%	3.625%
Notes [Member] | 0.41% CHF700 million bonds due 2023 (0.41% 2023 Swiss franc Bonds) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 702				713
Face amount | SFr			SFr 700,000,000
Interest rate, stated percentage	0.41%	0.41%	0.41%	0.41%
Notes [Member] | 2.25% notes due 2023 (2.25% 2023 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 750				750
Interest rate, stated percentage	2.25%	2.25%	2.25%	2.25%
Notes [Member] | 3.625% notes due 2024 (3.625% 2024 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,400				1,400
Interest rate, stated percentage	3.625%	3.625%	3.625%	3.625%
Notes [Member] | 3.125% notes due 2025 (3.125% 2025 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,000				1,000
Interest rate, stated percentage	3.125%	3.125%	3.125%	3.125%
Notes [Member] | 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 817				860
Face amount | €		€ 750,000,000
Interest rate, stated percentage	2.00%	2.00%	2.00%	2.00%
Notes [Member] | 2.60% notes due 2026 (2.60% 2026 notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,250				1,250
Interest rate, stated percentage	2.60%	2.60%	2.60%	2.60%
Notes [Member] | 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 584				606
Face amount | £				£ 475,000,000
Interest rate, stated percentage	5.50%	5.50%	5.50%	5.50%
Notes [Member] | 3.20% notes due 2027 (3.20% 2027 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,000				1,000
Interest rate, stated percentage	3.20%	3.20%	3.20%	3.20%
Notes [Member] | 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 860				893
Face amount | £				£ 700,000,000
Interest rate, stated percentage	4.00%	4.00%	4.00%	4.00%
Notes [Member] | 6.375% notes due 2037 (6.375% 2037 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 552				552
Interest rate, stated percentage	6.375%	6.375%	6.375%	6.375%
Notes [Member] | 6.90% notes due 2038 (6.90% 2038 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 291				291
Interest rate, stated percentage	6.90%	6.90%	6.90%	6.90%
Notes [Member] | 6.40% notes due 2039 (6.40% 2039 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 466				466
Interest rate, stated percentage	6.40%	6.40%	6.40%	6.40%
Notes [Member] | 5.75% notes due 2040 (5.75% 2040 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 412				412
Interest rate, stated percentage	5.75%	5.75%	5.75%	5.75%
Notes [Member] | 4.95% notes due 2041 (4.95% 2041 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 600				600
Interest rate, stated percentage	4.95%	4.95%	4.95%	4.95%
Notes [Member] | 5.15% notes due 2041 (5.15% 2041 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 974				974
Interest rate, stated percentage	5.15%	5.15%	5.15%	5.15%
Notes [Member] | 5.65% notes due 2042 (5.65% 2042 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 487				487
Interest rate, stated percentage	5.65%	5.65%	5.65%	5.65%
Notes [Member] | 5.375% notes due 2043 (5.375% 2043 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 261				261
Interest rate, stated percentage	5.375%	5.375%	5.375%	5.375%
Notes [Member] | 4.40% notes due 2045 (4.40% 2045 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 2,250				2,250
Interest rate, stated percentage	4.40%	4.40%	4.40%	4.40%
Notes [Member] | 4.563% notes due 2048 (4.563% 2048 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,415				1,415
Interest rate, stated percentage	4.563%	4.563%	4.563%	4.563%
Notes [Member] | 4.663% notes due 2051 (4.663% 2051 Notes) [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 3,541				3,541
Interest rate, stated percentage	4.663%	4.663%	4.663%	4.663%
Notes [Member] | Other notes due 2097 [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 100				$ 100

Financing arrangements (Details

Financing arrangements (Details Textual) - Notes [Member]	Sep. 30, 2019
4.563% 2048 Notes [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.563%
Effective interest rate	6.30%
4.663% 2051 Notes [Member]
Debt Instrument [Line Items]
Interest rate, stated percentage	4.663%
Effective interest rate	5.60%

Stockholders' equity (Share Rep

Stockholders' equity (Share Repurchase Program) (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Equity [Abstract]
Stock repurchased, Shares	6.2	13.1	15.9	8.7	18.2	56.4	35.2	83.4
Stock repurchased	$ 1,170	$ 2,349	$ 3,031	$ 1,713	$ 3,190	$ 10,787	$ 6,550	$ 15,690

Stockholders' equity (Details T

Stockholders' equity (Details Textual) - USD ($)	1 Months Ended						3 Months Ended
	Oct. 31, 2019	Sep. 30, 2019	Aug. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Mar. 31, 2018	May 31, 2019
Equity [Abstract]
Stock repurchase program, additional authorized amount											$ 5,000,000,000
Amount available for stock repurchases under a board approved stock repurchase plan		$ 3,600,000,000					$ 3,600,000,000
Dividends declared per share (in usd per share)	$ 1.45		$ 1.45		$ 1.45	$ 1.45	$ 1.45	$ 1.45	$ 1.32	$ 1.32
Dividends paid per share (in usd per share)		$ 1.45		$ 1.45	$ 1.45

Stockholders' equity (Component

Stockholders' equity (Components of AOCI) (Details) - USD ($) $ in Millions	3 Months Ended				9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	$ 10,794	$ 10,832	$ 12,500	$ 14,909	$ 12,500	$ 25,241
Foreign currency translation adjustments	(39)			(71)	(56)	(153)
Balance as of end of period	10,927	10,794	10,832	14,349	10,927	14,349
Foreign currency translation [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	(687)	(683)	(670)		(670)
Foreign currency translation adjustments	(39)	(4)	(13)
Income taxes	0	0	0
Balance as of end of period	(726)	(687)	(683)		(726)
Cash flow hedges [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	182	286	241		241
Unrealized gains	71	(96)	30
Reclassification adjustments to income	38	(36)	28
Income taxes	(23)	28	(13)
Balance as of end of period	268	182	286		268
Available-for-sale securities [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	36	(117)	(338)		(338)
Unrealized gains	35	161	218
Reclassification adjustments to income	3	2	4
Income taxes	(8)	(10)	(1)
Balance as of end of period	66	36	(117)		66
Other [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	4	(2)	(2)		(2)
Unrealized gains	0	0	0
Other		6
Balance as of end of period	4	4	(2)		4
AOCI [Member]
Increase (Decrease) in AOCI [Roll Forward]
Balance as of beginning of period	(465)	(516)	(769)	(873)	(769)	(679)
Foreign currency translation adjustments	(39)	(4)	(13)
Unrealized gains	106	65	248
Reclassification adjustments to income	41	(34)	32
Other		6
Income taxes	(31)	18	(14)
Balance as of end of period	$ (388)	$ (465)	$ (516)	$ (809)	$ (388)	$ (809)

Stockholders' equity (Reclassif

Stockholders' equity (Reclassifications out of AOCI) (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net	$ 114			$ 126			$ 517	$ 519
Income before income taxes	2,277			2,094			7,155	7,360
Provision for income taxes	(309)			(235)			(1,016)	(894)
Net income	1,968	$ 2,179	$ 1,992	1,859	$ 2,296	$ 2,311	6,139	6,466
Product sales [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Product sales	5,463			5,510			16,323	16,532
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Income before income taxes	(38)			(33)			(30)	(221)
Provision for income taxes	8			7			6	47
Net income	(30)			(26)			(24)	(174)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Available-for-sale securities [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net	(3)			(103)			(9)	(352)
Provision for income taxes	0			1			0	3
Net income	(3)			(102)			(9)	(349)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Foreign currency contract [Member] | Cash flow hedges [Member] | Product sales [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Product sales	26			3			62	(51)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cross-currency swap contract [Member] | Cash flow hedges [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net	(64)			(36)			(92)	(170)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Foreign currency contract [Member] | Cash flow hedges [Member] | Product sales [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Product sales	26			3			62	(51)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Cross-currency swap contract [Member] | Cash flow hedges [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net	$ (64)			$ (36)			$ (92)	$ (170)

Fair value measurement (Details

Fair value measurement (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Assets:
Interest-bearing securities	$ 20,227	$ 28,724
Equity securities	277	176
Derivatives:
Total assets	21,209	29,308
Derivatives:
Contingent consideration obligations	62	72
Total liabilities	546	648
Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	339	182
Derivatives:
Foreign currency and cross-currency swap contracts	6	26
Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	12	170
Derivatives:
Foreign currency and cross-currency swap contracts	478	401
Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	354	56
Derivatives:
Interest rate swap contracts		149
Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Equity securities	277	176
Derivatives:
Total assets	11,955	16,689
Derivatives:
Contingent consideration obligations	0	0
Total liabilities	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Quoted prices in active markets for identical assets (Level 1) [Member] | Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	0	0
Derivatives:
Interest rate swap contracts		0
Significant other observable inputs (Level 2) [Member]
Assets:
Equity securities	0	0
Derivatives:
Total assets	9,254	12,619
Derivatives:
Contingent consideration obligations	0	0
Total liabilities	484	576
Significant other observable inputs (Level 2) [Member] | Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	339	182
Derivatives:
Foreign currency and cross-currency swap contracts	6	26
Significant other observable inputs (Level 2) [Member] | Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	12	170
Derivatives:
Foreign currency and cross-currency swap contracts	478	401
Significant other observable inputs (Level 2) [Member] | Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	354	56
Derivatives:
Interest rate swap contracts		149
Significant unobservable inputs (Level 3) [Member]
Assets:
Equity securities	0	0
Derivatives:
Total assets	0	0
Derivatives:
Contingent consideration obligations	62	72
Total liabilities	62	72
Significant unobservable inputs (Level 3) [Member] | Foreign currency contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Significant unobservable inputs (Level 3) [Member] | Cross-currency swap contracts [Member]
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Derivatives:
Foreign currency and cross-currency swap contracts	0	0
Significant unobservable inputs (Level 3) [Member] | Interest rate swap contracts [Member]
Derivatives:
Interest rate swap contracts	0	0
Derivatives:
Interest rate swap contracts		0
U.S. Treasury notes [Member]
Assets:
Interest-bearing securities	1,167	2,663
U.S. Treasury notes [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	1,167	2,663
U.S. Treasury notes [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	0	0
U.S. Treasury notes [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
U.S. Treasury bills [Member]
Assets:
Interest-bearing securities	2,494	8,191
U.S. Treasury bills [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	2,494	8,191
U.S. Treasury bills [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	0	0
U.S. Treasury bills [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Other government-related debt securities - U.S. [Member]
Assets:
Interest-bearing securities	0	110
Other government-related debt securities - U.S. [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Other government-related debt securities - U.S. [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	0	110
Other government-related debt securities - U.S. [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Other government-related debt securities - Foreign and other [Member]
Assets:
Interest-bearing securities	925	932
Other government-related debt securities - Foreign and other [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Other government-related debt securities - Foreign and other [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	925	932
Other government-related debt securities - Foreign and other [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Corporate debt securities - Financial [Member]
Assets:
Interest-bearing securities	2,140	2,697
Corporate debt securities - Financial [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Corporate debt securities - Financial [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	2,140	2,697
Corporate debt securities - Financial [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Corporate debt securities - Industrial [Member]
Assets:
Interest-bearing securities	2,025	2,504
Corporate debt securities - Industrial [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Corporate debt securities - Industrial [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	2,025	2,504
Corporate debt securities - Industrial [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Corporate debt securities - Other [Member]
Assets:
Interest-bearing securities	537	562
Corporate debt securities - Other [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Corporate debt securities - Other [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	537	562
Corporate debt securities - Other [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Residential mortgage-backed securities [Member]
Assets:
Interest-bearing securities	516	1,422
Residential mortgage-backed securities [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Residential mortgage-backed securities [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	516	1,422
Residential mortgage-backed securities [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Other mortgage- and asset-backed securities [Member]
Assets:
Interest-bearing securities	43	469
Other mortgage- and asset-backed securities [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Other mortgage- and asset-backed securities [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	43	469
Other mortgage- and asset-backed securities [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Money market mutual funds [Member]
Assets:
Interest-bearing securities	8,017	5,659
Money market mutual funds [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	8,017	5,659
Money market mutual funds [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	0	0
Money market mutual funds [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	0	0
Other short-term interest-bearing securities [Member]
Assets:
Interest-bearing securities	2,363	3,515
Other short-term interest-bearing securities [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Assets:
Interest-bearing securities	0	0
Other short-term interest-bearing securities [Member] | Significant other observable inputs (Level 2) [Member]
Assets:
Interest-bearing securities	2,363	3,515
Other short-term interest-bearing securities [Member] | Significant unobservable inputs (Level 3) [Member]
Assets:
Interest-bearing securities	$ 0	$ 0

Fair value measurement (Detai_2

Fair value measurement (Details Textual) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Business Acquisition [Line Items]
Length of time hedged in foreign currency contracts (or less)	3 years
Long-term debt, fair value	$ 33,300		$ 35,000
Carrying value of debt	$ 29,791		$ 33,929
In-process Research and Development
Business Acquisition [Line Items]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)		$ 330
Other Government-related and Corporate Debt Securities [Member]
Business Acquisition [Line Items]
Investment maturity period	5 years

Derivative instruments (Details

Derivative instruments (Details Textual) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Foreign currency and cross currency swap contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amounts expected to be reclassified from AOCI into earnings over the next 12 months, foreign currency and cross-currency swaps	$ 97
Derivatives designated as hedging instrument [Member] | Foreign currency forward contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Notional amounts	4,600	$ 4,500
Derivatives designated as hedging instrument [Member] | Foreign currency option contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Notional amounts		21
Derivatives designated as hedging instrument [Member] | Interest rate swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Notional amounts	9,550	10,950
Derivatives not designated as hedging instrument [Member] | Foreign currency forward contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Notional amounts	$ 857	$ 737
Notes [Member] | 2.125% €675 million notes due 2019 (2.125% 2019 euro Notes) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Interest rate, stated percentage	2.125%

Derivative instruments (Cross-c

Derivative instruments (Cross-currency Swaps) (Details) - Cash flow hedge [Member] - Cross-currency swap contracts [Member] € in Millions, £ in Millions, SFr in Millions, $ in Millions	Sep. 30, 2019USD ($)	Sep. 30, 2019EUR (€)	Sep. 30, 2019CHF (SFr)	Sep. 30, 2019GBP (£)
1.25% 2022 euro Notes [Member]
Derivative [Line Items]
Notional amounts	$ 1,388	€ 1,250
0.41% 2023 Swiss franc Bonds [Member]
Derivative [Line Items]
Notional amounts	704		SFr 700
2.00% 2026 euro Notes [Member]
Derivative [Line Items]
Notional amounts	833	€ 750
5.50% 2026 pound sterling Notes [Member]
Derivative [Line Items]
Notional amounts	747			£ 475
4.00% 2029 pound sterling Notes [Member]
Derivative [Line Items]
Notional amounts	$ 1,111			£ 700
Euro Member Countries, Euro | 1.25% 2022 euro Notes [Member]
Derivative [Line Items]
Interest rates	1.30%	1.30%	1.30%	1.30%
Euro Member Countries, Euro | 2.00% 2026 euro Notes [Member]
Derivative [Line Items]
Interest rates	2.00%	2.00%	2.00%	2.00%
Switzerland, Francs | 0.41% 2023 Swiss franc Bonds [Member]
Derivative [Line Items]
Interest rates	0.40%	0.40%	0.40%	0.40%
United Kingdom, Pounds | 5.50% 2026 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	5.50%	5.50%	5.50%	5.50%
United Kingdom, Pounds | 4.00% 2029 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	4.00%	4.00%	4.00%	4.00%
United States of America, Dollars | 1.25% 2022 euro Notes [Member]
Derivative [Line Items]
Interest rates	3.20%	3.20%	3.20%	3.20%
United States of America, Dollars | 0.41% 2023 Swiss franc Bonds [Member]
Derivative [Line Items]
Interest rates	3.40%	3.40%	3.40%	3.40%
United States of America, Dollars | 2.00% 2026 euro Notes [Member]
Derivative [Line Items]
Interest rates	3.90%	3.90%	3.90%	3.90%
United States of America, Dollars | 5.50% 2026 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	6.00%	6.00%	6.00%	6.00%
United States of America, Dollars | 4.00% 2029 pound sterling Notes [Member]
Derivative [Line Items]
Interest rates	4.50%	4.50%	4.50%	4.50%

Derivative instruments (Effecti

Derivative instruments (Effective Portion of Unrealized Gain (Loss)) (Details) - Cash flow hedge [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Total unrealized gains	$ 71	$ 19	$ 5	$ 134
Foreign currency contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Total unrealized gains	176	41	245	233
Cross-currency swap contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Total unrealized gains	$ (105)	$ (22)	$ (240)	$ (99)

Derivative instruments (Hedged

Derivative instruments (Hedged Liabilities and Cumulative Amount) (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Derivative [Line Items]
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	$ 391	$ (53)
Current portion of long-term debt [Member]
Derivative [Line Items]
Carrying amounts of hedged liabilities	0	2,396
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	0	(3)
Carrying value with discontinued hedging relationships		1,000
Hedging adjustments on discontinued hedging relationships		3
Long-term debt [Member]
Derivative [Line Items]
Carrying amounts of hedged liabilities	9,811	9,361
Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities	391	(50)
Carrying value with discontinued hedging relationships	136	137
Hedging adjustments on discontinued hedging relationships	$ 36	$ 37

Derivative instruments (Summary

Derivative instruments (Summary of Income and Expense Line Items) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Interest and other income, net	$ 114	$ 126	$ 517	$ 519
Interest expense, net	(313)	(355)	(988)	(1,040)
Interest rate swap agreements [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) on fair value hedging relationships, Hedged items	(96)	48	(444)	278
Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments	96	(44)	447	(259)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Cross-currency swap contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Interest and other income, net	(64)	(36)	(92)	(170)
Product sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Product sales	5,463	5,510	16,323	16,532
Product sales [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedges [Member] | Foreign currency contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Product sales	$ 26	$ 3	$ 62	$ (51)

Derivative instruments (Fair Va

Derivative instruments (Fair Value of Derivatives) (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Assets
Total derivative assets, fair value	$ 705	$ 408
Liabilities
Total derivative liabilities, fair value	484	576
Derivatives designated as hedging instrument [Member]
Assets
Total derivative assets, fair value	705	407
Liabilities
Total derivative liabilities, fair value	484	576
Derivatives designated as hedging instrument [Member] | Foreign currency contracts [Member] | Other current assets/Other assets [Member]
Assets
Total derivative assets, fair value	339	181
Derivatives designated as hedging instrument [Member] | Foreign currency contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	6	26
Derivatives designated as hedging instrument [Member] | Cross-currency swap contracts [Member] | Other current assets/Other assets [Member]
Assets
Total derivative assets, fair value	12	170
Derivatives designated as hedging instrument [Member] | Cross-currency swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	478	401
Derivatives designated as hedging instrument [Member] | Interest rate swap contracts [Member] | Other current assets/Other assets [Member]
Assets
Total derivative assets, fair value	354	56
Derivatives designated as hedging instrument [Member] | Interest rate swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	0	149
Derivatives not designated as hedging instrument [Member]
Assets
Total derivative assets, fair value	0	1
Liabilities
Total derivative liabilities, fair value	0	0
Derivatives not designated as hedging instrument [Member] | Foreign currency contracts [Member] | Other current assets [Member]
Assets
Total derivative assets, fair value	0	1
Derivatives not designated as hedging instrument [Member] | Foreign currency contracts [Member] | Accrued liabilities [Member]
Liabilities
Total derivative liabilities, fair value	$ 0	$ 0

Contingencies and commitments (

Contingencies and commitments (Details) $ in Millions	Sep. 04, 2019patent	Aug. 22, 2019patent	Aug. 09, 2019lawsuit	Jul. 31, 2019lawsuit	Sep. 30, 2019patent	Sep. 30, 2019USD ($)
Humira Biosimilar Antitrust Class Actions [Member]
Loss Contingencies [Line Items]
Number of lawsuits | lawsuit			12
Sensipar Antitrust Class Actions [Member]
Loss Contingencies [Line Items]
Number of lawsuits | lawsuit				4
Hospira [Member]
Loss Contingencies [Line Items]
Damages awarded | $						$ 70
Kanjinti Genetech Litigation [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon | patent	4
Mvasi Patent Litigation, Genentech, Inc. (Genentech) and the City of Hope [Member]
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon | patent		1			6

Uncategorized Items - amgn-2019

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 29,000,000
AOCI Attributable to Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	(9,000,000)
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 38,000,000